



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19		A1	(11) International Publication Number: WO 97/00958
			(43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/AU96/00386		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 June 1996 (24.06.96)		Published With international search report.	
(30) Priority Data: PN 3706 22 June 1995 (22.06.95) AU PN 4990 23 August 1995 (23.08.95) AU PN 7983 9 February 1996 (09.02.96) AU			
(71) Applicant (for all designated States except US): ST. VINCENT'S HOSPITAL SYDNEY LIMITED [AU/AU]; Victoria Street, Darlinghurst, NSW 2010 (AU).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BREIT, Samuel, Norbert [AU/AU]; 33 Carlotta Avenue, Gordon, NSW 2072 (AU). BOOTCOV, Michelle [AU/AU]; 1/30 Hewlett Street, Bronte, NSW 2024 (AU).			
(74) Agent: F.B. RICE & CO.; 28A Montague Street, Balmain, NSW 2041 (AU).			
(54) Title: NOVEL TGF- β LIKE CYTOKINE			
(57) Abstract			
<p>A novel TGF-β like cytokine is described which has been designated pCLI3. Polynucleotide molecules encoding pCLI3 and biologically active fragments are also described as well as methods of expression and uses of the proteins, fragments and polynucleotide molecules.</p>			
<p>1 SEQUENCE 1-1000 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL TGF- β LIKE CYTOKINE

This invention relates to a novel TGF- β like cytokine and to isolated polynucleotide molecules encoding this protein. Particular applications of the invention may include treatments for wound and fracture healing, treatments and diagnostic assays for cancer, autoimmune and fibrotic diseases.

Macrophages play a central role in chronic inflammatory processes. The importance of these cells derives from the large variety of bioactive molecules that they produce and consequently, their capacity to amplify the inflammatory response. Their central role is also due to their capacity for communication with many other cells. For example, macrophage derived platelet derived growth factor (PDGF) is an important growth factor for both fibroblasts and smooth muscle cells. Another group of proteins of great significance in the relationship of macrophages with various connective tissue cells (e.g. fibroblasts, smooth muscle, endothelium osteoblasts etc) are the TGF- β superfamily cytokines, especially the TGF- β proteins themselves.

The TGF- β superfamily consists of growth and differentiation factors that share substantial structural homology (1). In vertebrates, individual families comprise the TGF- β proteins themselves, the growth and differentiation factors (GDF)(embryonic growth and development), the bone morphogenetic proteins (BMP)(induce cartilage and bone formation), the inhibins and activins (regulate FSH secretion by pituitary), and mullerian inhibitory substance (MIS)(regression of Mullerian duct during male sex differentiation). These proteins share important structural features. Their bioactivity resides in the carboxyterminal region of 100-150 amino acids. Over this region, members of this superfamily share about 30% sequence identity to TGF- β 1 and have 7 conserved cysteine residues. Within individual subgroups of the superfamily, proteins share 70% to 90% identity over the bioactive carboxy terminal domain. All superfamily members are thought to be cleaved at a cluster of basic residues 110 to 140 amino acids from the carboxy terminus of a precursor protein. Processing occurs immediately following a conserved RXXR sequence.

The three human TGF- β proteins share 80% sequence similarity over the bioactive portion of the molecule. The pro peptide (called latency-associated peptide (β 1-LAP)) displays less than 50% similarity between

family members. The $\beta 1$ -LAP is cleaved from the mature protein, but remains disulphide bonded to it. Separation of the $\beta 1$ -LAP is necessary to achieve biological activity (2).

5 The TGF- β proteins have been studied intensively because of their biological importance and therapeutic potential. Their biology and functions are well known and have been extensively reviewed (e.g. 2, 3, 4). In general terms they promote differentiation and differentiated function in a wide variety of cells. They are potent chemotactic factors for macrophages and fibroblasts and generally inhibit cell proliferation, perhaps because of
10 their role in differentiation. In the context of inflammation, TGF- β is a potent stimulator of fibroblast collagen and matrix protein synthesis, promotes angiogenesis, modulates expression of adhesion molecules and inhibits lymphocyte proliferation, production of some lymphokines and NK cell function. This molecule has been of great interest to the pharmaceutical
15 industry mainly, because of its demonstrable capacity to promote wound and fracture healing *in vivo*. TGF- β has also been heavily implicated in the pathogenesis of chronic inflammatory processes and mechanisms. Further, its local production has been used as a surrogate marker e.g. in active fibrotic diseases such as cirrhosis and it therefore has potential in the
20 diagnostic arena.

The present inventors have now isolated a polynucleotide molecule including a novel cytokine gene, clone 13 (CL13), which encodes a dimeric protein (pCL13) that appears to represent the first member of a new class of protein within the TGF- β superfamily.

25 Thus, in a first aspect, the present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding, or complementary to a sequence encoding, a protein designated pCL13 or a biologically active fragment thereof.

The isolated polynucleotide molecule may comprise a nucleotide
30 sequence the same as that of the CL13 clone described herein or may contain single or multiple nucleotide substitutions and/or deletions and/or additions thereto. The nucleotide substitutions which are envisaged may result in one or more conservative or non-conservative amino acid substitution(s). By conservative substitutions, the intended combinations are - G,A; V,I,L,M; D,E; N,Q; S,T; K,R,H; F,Y,W,H; and P,N α -alkylamino acids. The term
35 "nucleotide sequence" also includes sequences with sufficient homology to

hybridise with the nucleotide sequence under medium or, more preferably, high stringency conditions (5) and to nucleotide sequences encoding functionally equivalent sequences. In addition, the term "nucleotide sequence" includes sequences having at least 70%, more preferably 90%,
5 homology to clone 13 described herein or any portion thereof of > 10 nucleotides in length.

Most preferably, the isolated polynucleotide molecule comprises a nucleotide sequence substantially corresponding to the nucleotide sequence shown in Figure 1 or a portion thereof, or a complementary sequence
10 thereto. The term "portion thereof", in this regard, is to be understood as referring to portions of the nucleotide sequence which encode biologically active protein fragments and also, to portions of the nucleotide sequence, preferably > 10 nucleotides in length, which may be used in, or for the production of probes useful for, hybridisation assays.

15 The present invention also further extends to oligonucleotide primers for the above sequences, antisense sequences and homologues of said primers and antisense sequences, complimentary ribozyme sequences, catalytic antibody binding sites and dominant negative mutants of the polynucleotide molecule.

20 In a second aspect, the invention provides a protein designated pCL13, or a biologically active fragment thereof, in substantially pure form.

Preferably, the protein, or biologically active fragment thereof, comprises a monomeric polypeptide having an amino acid sequence substantially corresponding to the amino acid sequence shown in Figure 1 or
25 a fragment thereof.

Biologically active fragments thereof as mentioned in the first and second aspects refers to monomeric pCL13 polypeptides (with or without the propeptide) and other polypeptide or peptide portions (whether monomeric or dimeric) thereof which may consist of sequences which inhibit, mimic or
30 enhance the biological effect of the protein and dominant negative protein mutants, binding proteins including soluble receptors, other protein and/or glycosaminoglycans. The pCL13 propeptide may also represent a biologically active fragment of pCL13.

The protein, or biologically active fragment thereof, according to the
35 second aspect may be purified from natural sources (e.g. lungs, skin etc) or

cell lines, or may be produced recombinantly by any of the methods common in the art (5).

5 In a third aspect, the present invention provides an organism transformed with the polynucleotide molecule of the first aspect of the present invention.

The organisms which may be usefully transformed with the polynucleotide molecule of the first aspect include bacteria such as *E.coli* and *B.subtilis*, eukaryotic cell lines such as CHO, fungi, yeast, non-human animals and plants.

10 Transformed or transgenic, non-human animals may be established to, for example, overexpress CL13, pCL13 or a biologically active fragment thereof or, alternatively, generate antisense or ribozyme RNA molecules to inhibit native CL13 expression.

15 In a fourth aspect, the invention provides an antibody or fragment thereof specific to pCL13 or an antigenic portion thereof. The antibody may be polyclonal or monoclonal and may be produced by any of the methods common in the art.

20 It is also to be understood that the invention relates to kits for diagnostic assays, said kits comprising an antibody according to the fourth aspect of the present invention or nucleotide primers for PCR based assays.

In a fifth aspect the invention provides a protein or antigenic portion thereof, capable of binding to an anti-pCL13 antibody.

25 pCL13 is suitable for *in vivo* and *in vitro* procedures involving both human and animal cells. pCL13 is also suitable for both medical and veterinary use. In particular, pCL13 may be suitable for methods of treatment for any disease or condition beneficially treatable with TGF- β or another member of the TGF- β superfamily.

30 In a further aspect, the present invention provides a method of treatment to assist wound and/or fracture healing and/or ischaemic injury, comprising administering (for example, orally, topically, intravenously or subcutaneously) to a subject a preparation comprising a protein, or biologically active fragment thereof, according to the second or fifth aspects of the present invention, optionally in admixture with a suitable pharmaceutically acceptable carrier.

35 The protein, or biologically active fragment thereof, according to the second or fifth aspects may also be useful for one or more of the following:

- (i) Immunosuppression and anti-inflammatory effects for conditions such as autoimmune diseases or transplantation;
- (ii) Down regulation of leukocyte extravasation and motility in infective or inflammatory processes; and
- 5 (iii) Treatment of tumours through promotion of differentiation and antiproliferation action.

Such uses may be achieved by administration of the protein, or a biologically active fragment thereof, to a subject, or by gene therapy using all or part of the polynucleotide molecule of the first aspect. Such gene therapy
10 may be used to, for example, establish overexpression of CL13, or pCL13 or a biologically active fragment thereof in the host cell or, alternatively, to generate antisense or ribozyme RNA molecules to inhibit native CL13 expression.

It is also possible that inhibiting the action of pCL13 may provide
15 treatment of fibrotic/fibroproliferative disorders such as rheumatoid arthritis, atherosclerosis, pulmonary fibrosis, scleroderma, liver cirrhosis and keloids, and inhibition of tumour immunosuppression associated with conditions such as tumours, infections (especially viral) and chronic inflammatory diseases. These treatments may be achieved by using:

20 fragments or peptides of the pCL13 protein that inhibit receptor binding;

binding proteins for pCL13 including soluble receptors for this molecule, glycosaminoglycans, and other molecules which may inhibit or destabilise receptor ligand interaction;

25 antibodies directed at pCL13 or its receptor;

antisense or ribozyme strategies in which expression or stability of the pCL13 gene product is disturbed;

dominant negative mutants of the CL13 gene which, when expressed in a host cell, will destabilise or affect the activity of pCL13. (As the pCL13
30 protein is a dimer, a second gene product which has been modified may bind to the native pCL13 to form a heterodimer). Thus, an appropriately modified pCL13 variant may essentially render the pCL13 inactive through mechanisms such as enhanced degradation, aberrant intracellular trafficking and inhibition of export from the cell and inhibition of bioactivity.)

The invention thus further resides in a heterodimeric protein comprising a monomeric polypeptide of pCL13 together with a monomeric polypeptide of another protein from the TGF- β superfamily.

pCL13 or biologically active fragments thereof may be formulated
5 into standard pharmaceutical compositions suitable for the administration of proteins. Suitable formulations can be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA.

The dosage levels of pCL13 or biologically active fragments thereof
10 may be comparable to those useful for other members of the TGF- β superfamily. These levels are well understood in the art, and the precise dosage can be adjusted according to the condition of the subject, the mode of administration, and the judgement of the attending physician.

Possible diagnostic applications include diagnosis of cancer,
15 inflammatory and fibrotic disorders such as rheumatoid arthritis, cirrhosis and atherosclerosis in which enhanced synthesis of this gene may be present.

To facilitate the abovementioned applications for pCL13, it will be necessary to produce the protein in large quantities. However, extensive
20 studies with other protein members of the TGF- β superfamily, has revealed a number of difficulties in achieving expression in commercial amounts. For instance, expression in simple prokaryotic systems are largely unsuitable since members of the superfamily are cysteine knot dimeric proteins having a complex pattern of disulphide bond linkages.

The current strategy for expression of TGF- β superfamily proteins is
25 therefore to express the whole protein from a suitable DNA construct transfected into mammalian cells. However, this strategy necessitates treatment of the culture supernatant to separate processed (cleaved) bioactive mature protein from the propeptide and unprocessed (uncleaved)
30 material. This creates additional costs and difficulties because some of the expressed material is non-productive as typically 30%-50% of the secreted material will not be appropriately cleaved. The additional chromatographic procedure also generates extra losses of protein and incurs additional cost and time.

Previous efforts to express the mature bioactive portion of these proteins alone, has been unsuccessful, indicating that the propeptide is essential for achieving expression and secretion.

The present inventors, however, have been unexpectedly able to
5 achieve expression and secretion of pCL13 without expressing the leader or propeptide, using transfected mammalian cell cultures.

Thus, in a still further aspect, the present invention provides a method for producing a protein designated pCL13 or a biologically active fragment thereof, comprising transforming a suitable host organism with a
10 polynucleotide molecule comprising a nucleotide sequence encoding pCL13 or a biologically active fragment thereof, wherein said polynucleotide molecule is constitutively or inducibly expressed in said host organism.

Preferably, the nucleotide sequence encoding the pCL13 or a biologically active fragment thereof, does not comprise sequence encoding
15 the leader or propeptide of pCL13.

In place of sequences encoding the native leader or propeptide, it may be preferable to include within the polynucleotide molecule sequences encoding a heterologous leader (e.g. the follicle stimulating hormone (FSH) leader sequence) to assist expression.

Suitable host organisms may be any of those mentioned above in
20 respect to the third aspect of the present invention. However, preferred organisms include mammalian cell lines, yeast (e.g. *Pichia* and *Saccharomyces*) and non-human animals.

Expression of only the mature bioactive portion of pCL13 thereby
25 provides the following advantages:

- (i) Higher levels of expression; and
- (ii) No necessity to purify from propeptide and unprocessed full length CL13 protein.

Further, since it is not necessary to express the whole protein, it is
30 possible and simple to add amino-terminal epitope tags (e.g. FLAG and/or HIS) that can significantly assist with the purification and visualisation of recombinant protein.

Also, the capacity to express the mature bioactive portion of pCL13 in mammalian cells, indicates that it will also be able to be readily expressed
35 in yeast strains, such as the *Pichia pastoris* which is capable of secreting

disulphide linked proteins. Production of protein in yeast is much cheaper and easier than production by mammalian cells.

The invention will now be further described by way of the following non-limiting examples and with reference to the accompanying figures.

5

Brief Description of the Figures

Figure 1 provides the nucleotide sequence and putative amino acid sequence of clone 13 encoding pCL13.

Figure 2 shows CL13 expression in macrophage cultures.

10

Panel A. 15 µg total RNA was loaded per lane. Macrophage treatments were: lane 1, no treatment; lane 2, 1,000 U IFN γ overnight, lane 3, 1 µM retinoic acid overnight; lane 4, 1 µM retinoic acid overnight followed by 10 µg/mL LPS for 3 hours; lane 5, 10 µg/mL LPS for 3 hours.

15

Panel B. 20 µg total RNA was loaded per lane. Macrophage treatment were: lane 1, 1 µM retinoic acid for 3 days followed by 10 µg/ml LPS for 3 hours; lane 2, 1 µM retinoic acid overnight followed by 50 nM PMA for 3 hours; lane 3, 50 nM PMA for 3 hours; lane 4, untreated macrophages.

20

Figure 3 shows a northern blot analysis of clone 13 expression from macrophages treated with cytokines. All treatments were 3 hours. Lane 1, untreated macrophages; lane 2, 50 nM PMA; lane 3, 50 U/mL GM-CSF; lane 4, 100 U/mL M-CSF; lane 5, 100 U/mL IL1- β ; lane 6, 10ng/mL TGF- β ; lane 7, 10 U/mL PDGF-BB; lane 8, 50 U/mL IL-2; lane 9, 100 U/mL TNF- α , lane 10, 50 U/ml IL-6.

25

Figure 4 shows a northern blot analysis of the expression of clone 13 in U937. 20 µg total RNA was loaded per lane on a 1.2% agarose denaturing formaldehyde gel. Lane 1, no treatment; lane 2, 1 µM retinoic acid for 3 days, lanes 3, 4, 5, 6, 7, 1 µM retinoic acid for 3 days followed by 160 nM PMA for 20 min, 1 h, 2 h, 3 h and 12 h respectively; lane 8, 160 nM PMA for 3 h. Probes were labelled with 32 P. The blot was hybridized at 65°C and subjected to post hybridization washes and autoradiography.

30

Figure 5 provides a multiple sequence alignment of the carboxy terminal halves of pCL13 and other TGF- β superfamily members.

Figure 6 provides the nucleotide sequence and putative amino acid sequence for clone 13 in construct C13LB. The coding region for the bioactive portion of pCL13 commences with nucleotide 625.

35

Figure 7 provides the nucleotide sequence and putative amino acid sequence for clone 13 in construct FFC13S. The predicted bioactive portion of pCL13 commences with amino acid 92.

Figure 8 provides the nucleotide sequences and putative amino acid sequence for clone 13 in construct C13SA. The coding region for the bioactive portion of pCL13 commences with nucleotide 136.

Figure 9 shows a Western blot of purified recombinant pCL13 (FFC13S construct) visualised with anti-FLAG antibody.

Figure 10 provides a graph of the results obtained from glycosaminoglycan analysis in non-transfected (K1) and CL13 (FFC13S construct) transfected (P4N, 15 and 24) CHO cells using dimethyl-methylene blue (DMB) assay.

Figure 11 provides a graph of results obtained from collagen production assays of non-transfected (K1) and CL13 (FFC13S construct) transfected (P4N, 15 and 24) CHO cells.

Figure 12 provides graphs of results obtained from glycosaminoglycan production analysis in 3T3 (Figure 12A) and CCD (Figure 12B) cells following addition of various concentrations of pCL13 (expressed from construct C13SA).

Figure 13 provides graphical results obtained from collagen production analysis in CCD cells following addition of various concentrations of pCL13 (expressed from construct C13SA).

Figure 14 provides graphs of results showing growth factor activity under limiting serum conditions of pCL13 (expressed from construct C13SA) against TGF β in human baby foreskin fibroblasts (BFF) (Figure 14A) and 3T3 cells (Figure 14B).

Figure 15 provides graphs of results showing growth factor activity in the presence of serum of pCL13 (expressed from construct C13SA) and TGF β in BFF and 3T3 cells.

Figure 16 provides graphs of results showing the effect of pCL13 (expressed from construct C13SA) of pCL13, TGF β and IFN α 2b on the proliferation of U937 human monocytic cells (Figure 16A) and mono Mac 6 human monocytic cells (Figure 16B).

Figure 17 provides graphical results of an analysis of differing pCL13 (expressed from construct C13SA) concentrations on TNF- α production in human culture derived macrophages.

Figure 18 provides graphs of results showing the effect of pCL13 (expressed from construct C13SA) concentrations on the cytotoxicity of monocytes towards 5637 bladder tumour target cells (Figure 18A) and MDA-MB-231 breast tumour target cells (Figure 18B).

5 Figure 19A provides a micrograph of subcutaneous tissue taken from
a rat having been administered pCL13 (expressed from construct C13SA).

Figure 19B provides a micrograph of subcutaneous tissue taken from a control rat having been administered saline only.

Figure 20A shows the nucleotide sequences of CL13 variants (a1, b1, b2, d2, dd2, f1, u2 and h1) and the original CL13 (denoted C13).


Figure 20B shows a comparison of a portion of the putative amino acid sequence of the CL13 variants a1, b1, b2, d2, dd2, f1, u2 and h1.

Figure 21 provides the nucleotide sequence and putative amino acid sequence for clone 13 in construct C13SA/5H (HIS Thrombin cleavage site-FLAG-PKA-mature bioactive CL13 peptide). This construct has been used for expression in the yeast *Pichia pastoris*. HIS is 5 histadine residue motif to allow affinity purification using Nickel chelate chromatography. The thrombin site is to allow enzymic cleavage of the HIS from the rest of the sequence if required.

Figure 22 shows a western blot of culture medium from *Pichia pastoris* transformed with construct C13SA/5H. pCL13 protein is visualised using anti-FLAG antibody.

EXAMPLE 1: Characterisation of Clone 13

25 This clone hybridizes on Northern blot to a single species of mRNA of 1.2kb size and the gene has been localised by fluorescent *in situ* hybridisation to chromosome 19p13.1 (TGF-b1 is on 19q13.1 and MIS is on 19p13.3). The characteristics of the clone are outlined below.



The largest open reading frame codes for a high cysteine containing protein with a signal peptide. It bears strong homology to members of the

TGF- β superfamily (including TGF- β itself) when analysed using the *fasta* program on the ANGIS facility (opt scores 180-250). Extensive multiple sequence alignment using the CLUSTAL V program on GCG has been undertaken with the CL13 translated amino acid sequence (pCL13) and most members of this superfamily (see Figure 2).

Mature pCL13 is a dimeric protein with a conserved RXXR site that is likely to be involved in cleavage of a large pro-peptide with the encoded polypeptide decreasing from a predicted monomeric mass of about 34kDa to 13kDa. pCL13 has a potential glycosylation sites in its pro-peptide, but none in the mature protein, suggesting that glycosylation may be for intracellular targeting as it is in TGF- β .

In this superfamily the bio-activity resides in the carboxy terminal half of the molecule. There is strong conservation in this region between all superfamily members, especially in 7 of the cysteine residues. The full alignment data unequivocally demonstrates that pCL13 belongs to the TGF- β superfamily. In this superfamily within family identity is of the order of 70-80%. pCL13 does not display identity of this degree to any of the individual families and therefore appears to represent an entirely new and separate category within the TGF- β superfamily.

The full nucleotide sequence and putative amino acid sequence for clone 13 (CL13) is provided at Figure 1.

EXAMPLE 2: CL13 Gene Expression and Analysis of Biological Activity

Extensive studies of regulation of CL13 gene expression have been undertaken using the ^{32}P labelled clone insert and the results are summarised at Table 1. Some examples are also illustrated in Figures 2, 3 and 4. The results indicate that the 1.2 kb transcript was present at very low levels in untreated U937 and culture derived macrophages. Expression increased markedly with phorbol 12-myristate 13-acetate (PMA), but was not upregulated by LPS or interferon- γ (IFN- γ). Clone 13 was expressed strongly in macrophages treated with GM-CSF, M-CSF, IL2 or TNF- α and to a lesser extent with TGF- β , PDGF-BB or IL-6. There was also increased expression of CL13 mRNA in a human neonatal fibroblast cell line (CCD34Lu) in response to IGF-1, PDGF BB, TGF- β or

TNF- α and in human umbilical vein endothelial cells grown with ECGF. No expression of this gene was found in either resting or activated B or T lymphocytes/cell lines.

We can deduce reasonable hypotheses about the nature of the biological role of this protein on the basis of its expression and the general characteristics of the superfamily. CL13 expression could be induced in culture derived macrophages (MAC) by a variety of activation agents including cytokines and PMA but not LPS. Its expression was also induced in fibroblasts by activation and could not be induced at all in lymphocytes. As the endothelial cells tested were grown in the presence of ECGS, it is not possible to conclude whether expression is absent under resting conditions.

It may be of particular significance that TGF- β induces expression of CL13 in both fibroblasts and MAC. It is possible that some of the functions ascribed to TGF- β may be due to an autocrine or paracrine induction of TGF- β by CL13.

Many of the proteins in this TGF- β superfamily act on mesenchymal cells and it is anticipated that this will be true for pCL13. It is also thought that pCL13 may enhance the effector function of these cells, perhaps in a manner similar to TGF- β itself.

Lymphocytes and macrophages are intimately related in biological function. The fact that lymphocytes do not appear able to express CL13, but MAC express it in large amounts suggests the possibility that the lymphocyte may also represent a target for pCL13.

In summary, pCL13's properties and pattern of expression suggest that there may be some similarities to TGF- β . However, whilst it belongs to this superfamily, it can be said with some certainty, on the basis of sequence comparison, that pCL13 is one of a new class of proteins within this superfamily and is not an undescribed TGF- β protein (e.g. TGF- β 6).

TABLE 1
SUMMARY OF NORTHERN BLOT ANALYSIS OF CLONE 13[#]

	<u>TREATMENT</u>	<u>1.2 kb mRNA</u>
Monocytoid cell lines: HL60, KG1	untreated	-
	RA or PMA	-
	RA/PMA	+
Monocytoid cell line: U937	untreated	+
	IFN γ or LPS or both	+
	RA alone or with LPS	++
	PMA	+++
	RA/PMA (3 h)	++++
	RA /PMA (12 h)	+++++
	TGF β	++
	PMA/IL4	++
Macrophages ¹ (peripheral blood derived)	untreated	-
	RA	+
	PMA	+++
	RA /PMA	++++
	LPS or IFN-g	-
	IFN-g followed by IL2	+
	GM CSF	+
	IL 6 or IL2 or PDGF BB or TGF b	++
	M CSF or IL1 b or TNFa	+++
B cell lines ² , T cell lines, peripheral blood T cells	with or without PMA	-
Fibroblasts (CCD 34 Lu)	nil	-
	cytokines ³	+
Replicating endothelial cells ⁴	with or without cytokines ⁵	+

[#]Standardisation of the blots was achieved by probing with an oligonucleotide for 28S rRNA; All cell lines are human : 1. Macrophages are serum-free. 2. B cell lines were Sultan. Daudi, RPMI and U266. 3. Cytokines were IGF1, PDGF BB, TGF β and TNFa for 3 hrs. 4. HUVEC was grown with 20% FCS & growth factor (ECGF). 5. Cytokines were IFN γ , TNFa, IL1 β and IL2 for 3h.

EXAMPLE 3: Expression of Recombinant pCL13 and Antibody Generation**1. Prokaryotic expression of CL13**

5 This has been undertaken using the pGEX vector which generates a glutathione-S-transferase fusion protein. Material of the correct molecular weight was synthesised but was denatured and insoluble and hence unsuitable for purification. As a consequence, no further work was done with this vector because of the difficulties that are likely to be involved.

10 2. Eukaryotic expression of CL13**General Approach**

A number of DNA constructs based on the CL13 have been made. To some of these constructs the DNA sequence for the FLAG epitope has been added. This epitope codes for the 8 amino acid peptide (N-Asp-Tyr-Lys-Asp-
15 Asp-Asp-Asp-Lys-C) which codes for an enterokinase cleavage site is recognised by two commercially available monoclonal antibodies. A protein containing this marker peptide can then be affinity purified using these antibodies. Additionally the protein can also be detected using Western blotting or other antibody based assays. Addition of this small hydrophilic
20 peptide of the amino terminal region of the construct would not be expected to influence the bioactivity of the whole protein. However, if desired, enterokinase can be used to selectively cleave the FLAG peptide from the construction, without affecting the rest of the molecule.

Prediction of the signal sequence cleavage site of any protein is only
25 75-80% accurate. For this reason in some constructions it was necessary to use the follicle stimulating hormone (FSH) leader sequence. It is known to function in the eukaryotic cell to be used for transfection and its precise cleavage site is known. This was important to ensure that the FLAG peptide remained attached to the propeptide and was not removed with signal
30 sequence cleavage.

The following DNA constructs were made:

1. CL13: Unmodified full C13 sequence (Figure 1).
(CL13 leader sequence-Sequence for CL13 propeptide-Sequence for mature bioactive CL13 peptide).
- 35 2. C13LB: Full length CL13 with FLAG (Figure 6).

(FSH Leader sequence-FLAG-CL-13 propeptide-Sequence for mature bioactive CL13 peptide).

3. FFC13S: Bioactive CL13 with FLAG (Figure 7)

(FSH Leader sequence-FLAG sequence-about 40 amino acids propeptide-Sequence for mature bioactive CL13 peptide).

4. C13SA: Bioactive CL13 with FLAG (Figure 8)

(FSH leader - FLAG sequence - PKA - Mature bioactive CL13). PKA is the recognition sequence for protein kinase A to allow *in vitro* phosphorylation.

These constructs were cloned into two different mammalian cell expression vectors. These are the pCEP4 vector which is a semipermanent expression vector or the pCEP4 vector from which the EBNA gene sequence has been deleted to allow it to permanently integrate into the genome of the mammalian cell into which it is transfected. This allows for the development of a permanent cell line secreting this protein. The constructions have all been transferred into CHO and COS cells and either semipermanent or permanent cell lines bearing the transfectant established with the use of hygromycin to kill non transfectant bearing cells. Protein production and purification have been undertaken to date only in construction numbers 2, 3 and 4 (dominantly 3 and 4), bioactive CL13 with FLAG.

Cell Culture

Both COS and CHO cells are grown in Ham's F12 medium with 5% foetal calf serum (FCS) and 400ug/ml hygromycin (only in semipermanent cell lines). At confluence, medium is removed and replaced with HamF12 containing no serum or other supplements. The conditioned medium is removed after 3 days and used for purification of recombinant FLAG-CL13. The cells are then passaged and once more placed in serum containing medium.

Quantification

A dot blot assay has been established for quantification of recombinant FLAG containing proteins - either in culture supernatant or in purified form. Protein from culture supernatants (10-100ul) is deposited onto nitrocellulose using a dot-blot apparatus. The membrane is then

reacted with monoclonal anti-FLAG antibody and then biotinylated rabbit anti mouse IgG. This is then visualised by enhanced chemiluminescence on autoradiographic film. A standard curve is generated using a protein bacterial alkaline phosphatase (BAP) that has been engineered so that it contains 1 copy of the FLAG epitope at its amino terminus (Mr 50-55 kDa). The sensitivity of this assay is about 20ng of BAP.

When this assay was used to analyse the production of FLAG-CL13 it was found that cultures produced between about 25 and 400ng of recombinant protein per ml of culture supernatant. The best expression is seen with constructs 3 and 4.

Purification

Recombinant protein containing medium is incubated with sepharose beads to which anti-FLAG antibody has been conjugated. Approximately 1 ml of beads is used per 100 ml of conditioned medium. The sepharose and medium are incubated for 18hrs at 3deg C then beads are pelleted and poured into a minicolumn. They are then washed extensively with PBS and the recombinant protein is released with FLAG peptide. This is a very gentle but efficient procedure and ensures that the bioactivity of the recombinant protein is not damaged. The FLAG peptide is removed using gel filtration chromatography. The beads are then stripped with pH 3.5 glycine buffer and can then be re-used.

Figure 9 shows a Western blot of purified pCL13 protein from C13LB and C13SA constructs. The purified material was electrophoresed using SDS PAGE on a 15% gel under reducing and non reducing conditions prior to Western blotting and visualisation using monoclonal anti-FLAG antibody. The constructs migrate at molecular weights slightly higher than predicted, something that seems to be a function of the amino acids in the FLAG sequence and has been previously reported with the use of this epitope tag. However, there is the expected change in molecular weight associated with the use of reducing conditions indicating that the material is in the dimeric conformation.

The fact that these dimeric proteins are secreted into the medium also indicates that they are folded correctly as improperly folded and aggregated proteins expressed in eukaryotic cells are not secreted. The two constructs (FFC13SC and C13SC) which encode the bioactive protein alone,

both appear to be expressed at much higher levels than the native CL13 sequence which has only been modified to contain a FLAG epitope (C13LB). This is exemplified in Figure 9 which compares relative protein expression from constructs C13SA and C13LB.

5

EXAMPLE 4: Effect of pCL13 on Fibroblast Function

TGF- β stimulates fibroblast differentiated function and inhibits replication. In order to compare the function of pCL13 with TGF- β , the effect of pCL13 on fibroblast functions may be examined as follows.

10

a. Collagen and Glycosaminoglycan production

Neonatal lung fibroblasts (CCD34LU) can be grown to confluence and the growth medium replaced with DMEM containing 0.1% BSA. The cells can then be stimulated with recombinant pCL13 or TGF- β (10ng/ml) as a positive control. The culture supernatants can then be collected 18 hours later and assayed for total collagen and glycosaminoglycans (GAG). Collagen synthesis can be measured using a microtitre plate colorimetric assay developed in this laboratory which depends on the binding of total collagen to the dye sirius red (18). Total sulphated GAG can be measured with a colorimetric assay adapted in this laboratory for microtitre plate format and which has already been used for the *in vitro* determination of fibroblasts GAG synthesis (9,10). This assay is based on the metachromatic shift in absorption maximum for the cationic dye dimethyl-methylene blue consequent on binding the polyionic moieties of GAG (9,10).

15

20

25

b. Fibroblast replication

TGF- β is known to have a variable effect on *in vitro* fibroblast proliferation that probably depends on the balance between its capacity to down-regulate the PDGF receptor and the its induction of fibroblast PDGF synthesis. To determine whether pCL13 also modifies replication, a growth factor assay will be undertaken with CCD34Lu essentially as previously described (11, 12, 13)). These cells are sparsely plated at a concentration of about 1000 cells/ well (96 well plate). pCL13 protein or TGF- β (100ng/ml) (positive control) will be either added alone or in combination with a known

30

35

fibroblast growth factor present within fetal calf serum. Growth factor activity can be determined by ^3H -thymidine incorporation.

c. Collagenase activity

5 It would be expected that pCL13 inhibits the induction of collagenase activity. To test this, neonatal lung fibroblasts (CCD34LU) can be grown to confluence then the growth medium replaced with DMEM containing 0.1% BSA. The cells can then be stimulated with recombinant PMA to induce synthesis of collagenase in either the presence or absence of
10 pCL13 or TGF- β (50ng/ml - positive control). The supernatants can then be assayed for collagenase activity using our adaptation (14) of an assay (15) that is based on the degradation of 20ug of purified type I collagen that has been coated onto a microtitre plate. The undigested collagen is visualized by staining with sirius red and quantified photometrically.

15

EXAMPLE 5: Effect of pCL13 on Macrophage Function

The effects of TGF-b on macrophages are complex and in some instances apparently paradoxical. In general terms TGF-b has been
20 considered to be a potent macrophage chemotactic agent, a down-regulator of macrophage activation and a promoter of differentiation (3,4). To test the effect of pCL13 on macrophages, culture derived macrophages (MAC) will be used as the major cell source and will be grown free of serum in Iscove's Modified Dulbecco's Medium, using methods established by our laboratory
25 (15,16). As replicating cells become non adherent, it is possible to utilise both adherent, and undamaged non-adherent MAC for study.

a. Chemotaxis

This may be examined using a standard Boyden chamber chemotaxis
30 assay as previously performed (17). TGF- β (1pg/ml) will be used as the positive control for chemotaxis, and its response will be compared with that of pCL13.

b. Monocytoid cell differentiation

35 Both PMA and retinoic acid (RA) are potent inducers of CL13 mRNA. Both PMA, RA (as well as TGF- β) are known to induce the *in vitro*

differentiation of the primitive human monocytoid cell lines U937 and HL60 as well as bone marrow monocyte precursors. To examine the role of pCL13 in this process, the U937 and HL60 cell lines can be grown in the presence of TGF- β , pCL13 (with or without additional RA). Their differentiation will be
5 monitored by morphology, increased adherence and inhibition of replication (^3H -thymidine incorporation).

It has been previously demonstrated that human MAC grow in serum free medium, and their differentiation from monocytes to macrophages in vitro can be monitored by the expression of surface CD71, the transferrin
10 receptor (13,15). This is not seen on the surface of monocytes but is found on most MAC by day 7 of culture. Cells will be grown with TGF-b or pCL13 or interferon gamma then stained with fluoresceinated CD71 antibody and examined flow cytometrically on day 3 of culture (13). Promotion of
15 differentiation will be associated with earlier expression of this surface antigen.

c. Cytokine production

TGF- β has been reported to inhibit LPS induced production of TNF- α and IL-1. Further, as TGF- β induces pCL13 expression in a number of
20 situations, it is possible that some of the functions ascribed to TGF- β may be contributed to by pCL13. This can be examined using the above bioassays in which both TGF- β and pCL13 are active. The fibroblasts will be stimulated by TGF- β in the presence of blocking pCL13 antibody and pCL13 in the
presence of a blocking TGF- β antibody. If autocrine pathways are in
25 operation, the function in question should be reduced or inhibited by the blocking antibody. Antisense oligonucleotide inhibition experiments can also be undertaken.

EXAMPLE 6: Effect of pCL13 on Endothelial Cells

30 Like TGF- β , pCL13 may modify endothelial expression of adhesion molecules with subsequent downregulation of adhesion of neutrophils, monocytes or lymphocytes. Additionally pCL13 may modify angiogenesis and endothelial mediator production. This may be investigated by
35 investigating the effect of pCL13 on:

- (i) Leukocyte adherence to resting and cytokine activated vascular endothelium;
- (ii) Endothelial production of cytokines such as IL-8, MCP-1, IL-1, IL-6, and endothelin;
- 5 (iii) Endothelial prostanoid synthesis;
- (iv) Endothelial procoagulant activity; and
- (v) Angiogenesis (in vitro and vivo).

EXAMPLE 7: Effect of pCL13 on Lymphocyte Function

10

Like TGF- β , pCL13 may act as an immunosuppressive agent. This can be investigated by determining the effect of pCL13 on:

- (i) T and B cell proliferation;
- (ii) Immunoglobulin synthesis;
- 15 (iii) LAK cell and NK cell activity; and
- (iv) Production in vitro of cytokines (protein and/or mRNA) such as IL-2, IFN-g, IL-4, IL-5, IL-10.

EXAMPLE 8: Effect of pCL13 on Tumor Cell Proliferation

20

pCL13 may like TGF- β inhibit tumor cell replication and promote tumor differentiation. This can be investigated by determining the effect of pCL13 on:

- (i) In vitro investigation of the proliferation of a wide range of tumour cell lines available through the ATCC; and
- 25 (ii) Observing change in tumor phenotype towards a more differentiated form (e.g. change from non-adherent to adherent phenotype).

EXAMPLE 9: Effect of pCL13 on Glycosaminoglycan Production by Non-transfected and transfected CHO cells.

30

The effect of pCL13 on glycosaminoglycan production was investigated using non-transfected and transfected CHO cells. Figure 10 shows glycosaminoglycan analysis in the non-transfected (KI) and CL13
35 transfected (P4N, 15 and 24) CHO cells using dimethyl-methylene blue (DMB) assay (9, 10). P4N, 15 and 24 produce increasing amounts of pCL13

respectively. Cells were cultured in DMEM/F-12 medium containing 5% FCS for 5 days. Cells were then changed to FCS-free DMEM for 24 hours. To 100 µl cell culture medium 100 µl DMB dye was added and the absorbance was read at 492 nm immediately. The results represent the mean
5 +/- SD of triplicate wells.

EXAMPLE 10: Effect of pCL13 on Collagen Production by Non-transfected and Transfected CHO Cells

10 The effect of pCL13 on collagen production was investigated. Figure 11 shows the effect of pCL13 on collagen production by non-transfected (K1) and CL13 transfected (P4N, 15 and 24) CHO cells. P4N, 15 and 24 produce increasing amounts of pCL13 respectively. Cells were cultured in DMEM/F-12 medium containing 5% FCS for 5 days. Cells were then
15 changed to FCS-free DMEM for 24 hours. The amount of collagen produced by these cells was determined using a Biodot apparatus. Culture supernatant (50 µl) was placed on nitrocellulose membrane. The membrane was washed in 100 µl PBS and dried. Collagen retained in the nitrocellulose membrane was stained with 0.1% Sirius red dye (18). Individual spots were
20 cut out and eluted with 0.1 N NaOH and absorbance was read at 550 nm. The results represent the mean +/- SD of triplicate wells.

Examples 11 to 16 described hereinafter were conducted with the C13SA construct or pCL13 produced from the C13SA construct. As
25 described above, the C13SA construct varies from CL13 in that it includes no propeptide encoding sequences.

EXAMPLE 11: Effects of pCL13 on matrix protein production

30 a. Glycosaminoglycan production

Figure 12 shows the effect of pCL13 on ³⁵S-labelled-proteoglycan production in 3T3 (mouse fibroblasts) and neonatal human lung fibroblasts (CCD 34 Lu) after 24 hour incubation. Confluent cells were changed to RPMI culture medium containing 0.1% BSA and 50 µg/ml ascorbic acid for 24
35 hours. Cells were then incubated with different pCL13 concentrations in the presence of 10 µCi/ml [³⁵S] sulphate for 24 hours. At the end of the

incubation period medium was removed and protease inhibitors were added. Proteoglycans present in the extracellular matrix were extracted using 4M guanidine hydrochloride containing protease inhibitors for one hour at 4°C. Total proteoglycan production in the medium and the cell fraction was
5 determined using Sephadex G-25 chromatography columns (19). The results represent the mean +/-SD of triplicate wells.

In 3T3 cells, after 24 hour incubation period, pCL13 caused a dose dependent increase in the proteoglycan production. A 92% increase was observed at 25ng/ml pCL13 concentrations and 60% increase was seen at 6.7
10 and 2.2 ng/ml pCL13 concentration. In comparison TGF- β at 20ng/ml elevated proteoglycan production by 95%. In CCD 34Lu cells, pCL13 at 50ng/ml caused 23% increase in the proteoglycan production and 6% increase at 25ng/ml pCL13 concentration. In comparison TGF- β at 10ng/ml elevated proteoglycan production by 36%.

15

b. Collagen production

Figure 13 shows the effect of pCL13 on collagen type 1 production in neonatal lung fibroblasts (CCD 34 Lu). Confluent cells were changed to DMEM culture medium containing 0.1% BSA and 50 μ g/ml ascorbic acid for
20 24 hours. Cells were then incubated with different pCL13 concentrations in the presence of 50 μ g/ml b-aminopropionitrile for 24 hours. At the end of incubation period the amount of collagen present in the medium was determined using an ELISA. Briefly, supernatants from treated and non-treated fibroblasts as well as type 1 collagen standards were incubated for 72
25 hours at 4°C in 96-well microtitre plates (NUNC). At the end of incubation period plates were washed, blocked with 4% bovine serum albumin in phosphate buffered saline, incubated with collagen type 1 monoclonal antibody (Sigma). The plates were then rewashed and biotinylated mouse IgG was added and followed by streptavidin complex. After the addition of
30 substrate, plates were read at 490/405 nm on a plate reader. The results represent the mean +/-SD of triplicate wells. pCL13 at 50ng/ml caused 140% increase in the collagen production, 190% increase at 25ng/ml and 11% at 5ng/ml concentration. In comparison TGF- β at 10ng/ml elevated collagen production by 34% after 24 hours. The relatively poor TGF- β response has
35 occurred because TGF- β requires 48-78 hours to achieve maximal effect.

EXAMPLE 12: Effect of pCL13 on fibroblast replication**a. Growth under limiting serum conditions**

The growth factor activity of pCL13 and transforming growth factor
5 beta (TGF β) on growth-arrested BFF (human baby foreskin fibroblasts) and
3T3 (mouse fibroblasts) cells was determined. The cytokines were added to
BFF and 3T3 cells in 0.2% foetal bovine serum (FBS) media to determine
whether they were true growth factors which could stimulate a resting cell to
progress through the cell cycle and undergo division. The growth factor
10 assay was performed as previously described (11, 12). In brief, the cells were
plated at 1.2×10^3 cells/well in 200mL of growth-arresting medium (0.2% FBS)
for 72h. The media was then replaced with fresh 0.2% FBS media with or
without cytokines and 0.5mCi/well of [3-H] Thymidine for a further 72h.
The cells were then harvested with an automated cell harvester and the
15 thymidine uptake into proliferating cells was counted on a liquid
scintillation analyser. The controls included 0.2% FBS media only, 10% FBS
media only (normal growth media), and pCL13 diluent (0.1% CHAPS) in
0.2% FBS media.

The results shown in Figure 14 indicate that pCL13 appears to have
20 true growth factor activity on both human BFF. TGF β appears to be
inhibitory for BFF cells. Neither pCL13 nor TGF β exhibit growth factor
activity on 3T3 under the conditions of this assay.

b. Growth in the presence of serum

The growth factor activity of pCL13 and transforming growth factor
25 beta (TGF β) on growth-arrested BFF (human baby foreskin fibroblasts) and
3T3 (mouse fibroblasts) cells was determined. The cytokines were added to
BFF and 3T3 cells in 2% foetal bovine serum (FBS) media to determine
whether they were growth enhancing substances which could enhance the
rate at which the cells moved through the cell cycle. The growth factor
30 assay was performed as previously described (11, 12). In brief, the cells were
plated at 1.2×10^3 cells/well in 200ml of growth-arresting medium (0.2% FBS)
for 72h. The media was then replaced with fresh 2% FBS media with or
without cytokines and 0.5mCi/well of [3-H] Thymidine for a further 72h.
35 The cells were then harvested with an automated cell harvester and the
thymidine uptake into proliferating cells was counted on a liquid

scintillation analyser. The controls included 2% FBS media only, 10% FBS media only (normal growth media), and pCL13 diluent (0.1% CHAPS) in 0.2% FBS media.

The results (Figure 15) show that pCL13 had a growth-enhancing effect on human BFF and murine 3T3 cells. TGF β appears to be inhibitory for BFF cells but to have growth-enhancing activity at low concentration on 3T3 cells.

EXAMPLE 13: Effects of pCL13 on replication of human monocytoid cell lines

pCL13 was compared with transforming growth factor beta (TGF β) and interferon alpha 2b (IFN α 2b), for their antiproliferative effect on the cell line U937 (a human monocyte-like histiocytic lymphoma) and Mono Mac 6 (a monoclastic leukemia cell line). The cells were plated at 3×10^4 cells/well in 200mL of 10% FBS (foetal bovine serum) medium with or without cytokines. For the final 6h of a 48h incubation period, the wells were pulsed with 0.5mCi/well of [3-h] Thymidine. The cells were then harvested with an automated cell harvester and the thymidine uptake into proliferating cells were counted on a liquid scintillation analyser. The controls include 10% FBS medium alone and pCL13 diluent in 10% FBS medium.

The results (Figure 16) indicate that two batches of pCL13, B447 and B448A, at concentrations of 10 and 100ng/ml have a small antiproliferative effect on two human cell lines of monocytic origin. This contrasts with the stronger antiproliferative effects of TGF β (2 and 20ng/ml) and IFN α 2b (10^3 and 10^5 U/ml) on U937 and Mono Mac 6 cells.

EXAMPLE 14: Effects of pCL13 on macrophage production of TNF

The data in Figure 17 shows the effect of different pCL13 concentration on LPS stimulated TNF- α production from human culture derived macrophages. Monocytes were purified by elutriation from buffy coats and cultured in Iscove's medium containing 0.1% BSA (13, 16). On day 5, cells were incubated with different pCL13 concentrations in the presence of 10 μ g/ml LPS in the Iscove's medium for 24 hours. At the end of incubation period medium was removed and the amount of TNF- α present

was determined using a sandwich ELISA (Genzyme). The results show that pCL13 caused inhibition of LPS induced TNF- α production. A 47% inhibition was observed at 20ng/ml pCL13 and a 27% inhibition was seen at 7ng/ml of pCL13. In comparison TGF- β only brought about 10% reduction at
5 20ng/ml.

EXAMPLE 15: Effects of pCL13 on tumor cytotoxicity

The direct effect of pCL13 and TGF β on tumour target cells (5637
10 bladder carcinoma and MDA-MB-231 breast adenocarcinoma) and the effect of pCL13 and TGF β on monocyte-mediated killing of tumor cells was examined by measuring the release of radiolabelled DNA from lysed tumour target cells. The cytotoxicity assay was performed as previously described (20). Tumour target cells (labelled while in the exponential growth phase
15 with 20 μ Ci of [3 H] Thymidine/ 1×10^6 cells for 24h) were added to the monocytes (effectors) at an effector:target (E:T) ratios of 10:1 for 72 h. The cells were then centrifuged and the supernatants counted in scintillation fluid on a liquid scintillation analyser. The controls included untreated tumour cells, untreated tumour cells co-cultured with monocytes and
20 cytokine diluent alone. TGF β and pCL13 were incubated with monocytes for 48h.

The results are shown at Figure 18. Neither pCL13 nor TGF β had a direct cytotoxic effect on the 5637 or MDA-MB-231 tumour lines. However pCL13 enhanced the ability of monocytes to kill 5637 cells. pCL13 also
25 enhanced the monocyte-mediated killing of T24 (bladder carcinoma), J82 (bladder carcinoma), T47D (breast ductal carcinoma) and JCPL (ovarian carcinoma)(data not shown).

EXAMPLE 16: In vivo Effects of pCL13

30

Rats (Fisher F343) were injected subcutaneously on their backs with 0.1ml of three concentrations of pCL13, a negative saline control and TGF β . The injections were widely separated and each animal was administered with the whole panel of 5 injections. The amounts of pCL13 injected were
35 60ng, 30ng and 2ng. The dose of TGF β administered was 10ng. The animals were then sacrificed at intervals commencing at 3 hours and up to 2 weeks

following administration. Three animals were used for each time point, and following sacrifice the areas in which material had been administered was excised, formalin fixed, mounted, then stained with haematoxylin and eosin. The material was then evaluated microscopically.

5

a. Macroscopic Changes

There was no macroscopic difference between the biopsies in any of the animals, under any of the various conditions other than at the two week time point. At the two week time point however, the biopsies, only of the areas with the two highest doses of pCL13, showed obvious macroscopic differences in the area between the muscle and skin. This area seemed somewhat expanded and had a white glistening appearance, suggestive of excess matrix protein deposition.

10

b. Microscopic Evaluation

No differences were seen on histological sections at the three hour time points. However at the day one (24 hour) time point the areas in which the two highest concentrations of pCL13 had been administered demonstrated a mononuclear cell infiltrate which was somewhat patchy in character and was present dominantly in the subcutaneous tissue (Figure 19A). No similar changes were observed in either the negative saline control (Figure 19B) or TGF β at a dose of 10ng/ml. The infiltrate seemed to be present maximally at days one and two and be markedly diminished or absent from day four onwards. These findings suggest that pCL13 was chemotactic for macrophages and or lymphocytes.

20

25

This study was not undertaken in such a manner as to be able to supply good quantitative data on the amount of collagen that was present in the areas where the two substances were administered. However in conjunction with the macroscopic appearance, it appears likely that the amount of collagen was increased in the samples containing the two highest doses of clone 13, at least at the two week time point.

30

EXAMPLE 17: Clone 13 Variants

35

Re-screening was undertaken using a fetal lung cDNA library using a portion of the coding sequence of clone 13 as a probe. This was undertaken

in order to determine the existence of clone 13 variants. Using this approach a number of additional clones (a1, b2, h1, b1, d2, dd2, f1 and u2) were obtained and the sequence of these clones is illustrated in Figure 20A which shows the nucleotide sequence and Figure 20B which shows a portion of the translated open reading frame. It also compares the sequences with that of the original clone 13 sequence (C13). From Figure 20B, it can be seen that the translated coding region of these clone 13 variants displays only minor differences. These occur at amino acids 9, 48 and 202. These are all in the propeptide region and are likely to represent genetic differences between the individuals whose RNA was used to prepare the cDNA library. However, at the DNA level, there is substantial variation dominantly in the 5' untranslated region, but to a lesser extent in the 3' untranslated region. Whilst these variants may well be important in areas such as transcriptional regulation they are untranslated and hence cannot affect bioactivity.

Some of the clones isolated and displayed in Figure 20A (e.g. b2 and h1) even though they have very long 5' untranslated region, still do not represent the complete coding sequence. This can be ascertained as when the 5' untranslated region is used as a probe, on northern blots, hybridisation to a band of approximately 7kb is demonstrable. The reasons for this marked length variation are unclear but could include alternate splicing of an untranslated exon, the use of alternate transcriptional start sites or even gene duplication.

EXAMPLE 18: Expression of clone is using a yeast eukaryotic system

25

The bioactive region of clone 13, modified at its amino terminus so as to contain a number of additional marker epitopes (construct C13SA/5H - Figure 21) was cloned into the pPIC9 plasmid. This plasmid was then used to transform the yeast *Pichia pastoris* according to the manufacturers instructions (Invitrogen Corp.). Yeast, successfully transformed by this plasmid were selected on the basis of methanol sensitivity. Colonies of yeast were then grown for two days, in suspension as per the manufacturers instructions. Culture medium was collected and an aliquot subjected to SDS-PAGE followed by western blotting. pCL13 containing bands were visualised using the anti-FLAG M2 antibody using standard procedures. Electrophoresis was carried out under both reducing and non-reducing

conditions. It can be seen that large amounts of the protein are produced which are easily detectable with unconcentrated yeast culture medium, indicating secretion of the protein in an appropriate manner (Figure 22). The molecular weight approximates that expected on the basis of the amino acid composition and the doubling of the molecular weight under non-reducing conditions (Figure 22) indicates that the protein is, as expected, a disulphide bonded dimer. This is the correct structural configuration and indicates that the protein has been processed and secreted by the yeast organism in an appropriate manner.

The capacity to express this complex dimeric, protein with a high disulphide bond content in yeast systems is highly advantageous as it dramatically lowers the cost of production per unit quantity of protein and makes it far more suitable as a biopharmaceutical compared with material produced by mammalian cells.

Whilst this work has been undertaken with the yeast *Pichia pastoris*, it is quite likely that similar secretion will occur with a range of yeast organisms transduced with an appropriate yeast expression vector. As the bioactive region being expressed does not contain potential n-glycosylation sites, the hyperglycosylation, that sometimes occurs with mammalian proteins expressed by yeast strains, is not an issue.

REFERENCES

1. Burt DW. Evolutionary grouping of the transforming growth-factor-b superfamily. *Biochem Biophys Res Commun.* 1992; 590-595.
2. Miyazono K, Ichijo H, Heldin C-H. Transforming growth factor-b: Latent forms, binding proteins and receptors. *Growth factors* 1993;8:11-22.
3. Wahl. SM. Transforming growth factor beta in inflammation: A cause and a cure. *J Clin Immunol.* 1992;12:61-74.
4. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-b. *Growth factors.* 1993; 8:1-9.
5. Sambrook J., Fritsch EF. & Maniatis T. (1989) *Molecular Cloning: A Laboratory Manual.* Second Edition, Cold Spring Harbor Laboratory Press, New York.

6. Current Protocols in Molecular Biology, Ausubel FM et al, eds. Green Publishing Associates, New York. 1989
7. Ma J, Walsh B, Chen S-L, Penny R, Breit SN. Restoration of antibody activity of a monoclonal anti RNP antibody by HPLC under dissociative conditions: Demonstration of blocking of the antibody binding sites with antigen released from effete hybridoma cells. J Immunol methods. 1992; 155: 121-127.
8. Miyazono K, Thyber J, Heldin C-H. Retention of the TGF- β 1 precursor in the golgi complex in a latent endoglycosidase H sensitive form. J Biol Chem. 1992; 267: 5668-75.
9. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986; 883: 173-177.
10. E.M Foulcher. MSc qualifying thesis submitted to UNSW entitled: Glycosaminoglycans and their role in inflammation. 1992.
11. Thornton SC, Por SB, Walsh B, Penny R, Breit SN. The interaction of immune and connective tissue cells: 1. The effect of lymphokines and monokines on fibroblast growth. J Leukocyte Biol. 1990; 47:312-320.
12. Thornton SC, Por SB, Shelley L, Penny R, Breit SN. Identification of the major fibroblast growth factors spontaneously released in inflammatory arthritis as PDGF and TNF alpha. Clin Exp Immunol. 1991; 86:79-86.
13. Bennett S, Por SB, Cooley MA, Breit SN. In vitro replication dynamics of human culture-derived macrophages in a long term serum free system. J Immunol. 1993; 150: 2364-2371.
14. Nethery A. Anal Biochem. 1986; 159: 390-395
15. Katelaris A. Doctor of Medicine thesis submitted to UNSW and entitled: Graft versus host disease as a model of scleroderma - An investigation into the interaction of the immune system and connective tissue using a murine model. 1991.
16. Bennett S, Por S, Stanley ER, Breit SN. Monocyte proliferation in cytokine-free, serum free system. J Immunol Methods. 1992;153:201-212.
17. Breit SN, Robinson JP, and Penny R. The effect of alpha 1 antitrypsin on phagocyte function. J Lab Clin Immunol. 1983; 10:147-149.

18. Walsh B, Penny R, Breit SN. Microplate reader - based quantitation of collagens. *Anal Biochem* 1992; 203:187-190.
19. Bansal M.K., Ross A.S.A., and Bard J.B.L., Does chondroitin sulphate have a role to play in the morphogenesis of the check primary
5 corneal stroma? *Developmental Biology* 1989; 133: 185-195.
20. Pryor K, J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky and R. Penny. *Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing*, *British Journal of Cancer*, 1995; 71: 801-807.

10

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the
15 invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:-

1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding, or complementary to a nucleotide sequence encoding, a protein designated pCL13 or a biologically active fragment thereof.
5
2. An isolated polynucleotide molecule comprising a nucleotide sequence substantially corresponding to that shown in Figure 1, a portion thereof which encodes a biologically active fragment of pCL13, or a nucleotide sequence complementary thereto.
10
3. An isolated polynucleotide molecule comprising a nucleotide sequence substantially corresponding to a mutant, variant or derivative sequence of that shown in Figure 1, or a nucleotide sequence complementary thereto.
15
4. A polynucleotide molecule according to claim 3, wherein the nucleotide sequence substantially corresponds to a variant nucleotide sequence selected from a1, b1, b2, d2, dd2, f1, h1 and u2 as shown in Figure 20A, or a nucleotide sequence complementary thereto.
20
5. A polynucleotide molecule according to claim 1, wherein the protein comprises a polypeptide having an amino acid sequence selected from those shown in Figure 20B.
25
6. A polynucleotide molecule according to claim 1, wherein the protein comprises a polypeptide having an amino acid sequence substantially as shown in Figure 1.
7. An isolated polynucleotide molecule comprising a nucleotide sequence hybridisable to the nucleotide sequence shown in Figure 1 under medium stringency conditions.
30
8. An isolated polynucleotide molecule comprising a nucleotide sequence hybridisable to the nucleotide sequence shown in Figure 1 under high stringency conditions.
35

9. A polynucleotide molecule according to claim 7 or 8 capable of being utilised as a probe or primer for a polynucleotide sequence encoding a protein designated pCL13.
- 5
10. A polynucleotide molecule according to claim 7 or 8 being of a length greater than 10 nucleotides.
11. An isolated polynucleotide molecule comprising a nucleotide sequence having at least 70% homology to the nucleotide sequence shown in Figure 1.
- 10
12. An isolated polynucleotide molecule comprising a nucleotide sequence having at least 90% homology to the nucleotide sequence shown in Figure 1.
- 15
13. A polynucleotide molecule according to any one of the preceding claims, wherein the nucleotide sequence encoding the pCL13 or biologically active fragment thereof does not comprise sequence encoding the pCL13 leader or propeptide.
- 20
14. A polynucleotide molecule according to claim 13, wherein said nucleotide sequence encoding the pCL13 or biologically active fragment thereof includes sequence encoding a heterologous leader.
- 25
15. A polynucleotide molecule according to claim 14, wherein said heterologous leader is the follicle stimulating hormone (FSH) leader.
16. A polynucleotide molecule according to any one of the preceding claims, wherein the nucleotide sequence encoding the pCL13 or biologically active fragment thereof includes sequence encoding an epitope tag.
- 30
17. A polynucleotide molecule according to claim 16, wherein the epitope tag is FLAG and/or HIS.
- 35

18. A polynucleotide molecule according to any one of the preceding claims, wherein the polynucleotide molecule is DNA.
19. A vector comprising a DNA molecule according to claim 18 operably
5 linked to a suitable promoter.
20. A vector comprising a DNA molecule according to claim 19, the DNA molecule being operably linked in opposite orientation to a suitable promoter such that expression proceeds 5' to the 3' terminus to produce
10 antisense RNA.
21. A vector according to claim 20, wherein said DNA molecule includes or is linked to a nucleotide sequence encoding a ribozyme domain.
- 15 22. A protein designated pCL13 in substantially pure form.
23. A protein according to claim 22, wherein the protein comprises a monomeric polypeptide(s) having an amino acid sequence selected from those shown in Figure 20B.
20
24. A protein according to claim 22, wherein the protein comprises a monomeric polypeptide(s) having an amino acid sequence substantially as shown in Figure 1.
- 25 25. A biologically active fragment of a protein according to any one of claims 22 to 24.
26. A biologically active fragment according claim 25, wherein said biologically active fragment corresponds to a pCL13 propeptide or fragment
30 thereof.
27. A protein or antigenic portion thereof, which binds to an anti-pCL13 antibody.

28. A non-human organism transformed with a polynucleotide molecule according to any one of claims 1 to 18 or a vector according to any one of claims 19 to 21.
- 5 29. A non-human organism according to claim 28 selected from eukaryotic cell lines, yeast, animals and plants.
30. An antibody or fragment thereof which specifically binds to the protein designated pCL13 or an antigenic portion thereof.
- 10 31. A method of producing a protein designated pCL13 or a biologically active fragment thereof, comprising transforming a suitable host organism with a polynucleotide molecule according to any one of claims 1 to 12, wherein said polynucleotide molecule is constitutively or inducibly
15 expressed in said host organism.
32. A method of producing a protein designated pCL13 or a biologically active fragment thereof, comprising transforming a suitable host organism with a polynucleotide molecule according to any one of claims 13 to 17,
20 wherein said polynucleotide molecule is constitutively or inducibly expressed in said host organism.
33. A method according to claim 31 or 32, wherein said host organism is selected from eukaryotic cell lines and yeast.
- 25 34. A method according to claim 33, wherein said host organism is a yeast.
35. A method according to claim 34, wherein said yeast is *Pichia pastoris*.
- 30 36. A method of treatment of a disease or condition in a subject which is beneficially treatable with TGF- β , comprising administering to said subject a preparation comprising a protein or biologically active fragment thereof according to any one of claims 22 to 27 or, alternatively, an agent for
35 reducing the expression or activity of native pCL13, optionally in admixture with a pharmaceutically acceptable carrier.

37. A method of treatment of a disease or condition in a subject, said disease or condition being selected from wound and/or fracture healing, ischaemic injury, cancer, autoimmune diseases, chronic inflammatory
5 diseases, immunosuppression, fibrotic/fibroproliferative disorders such as rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, scleroderma, liver cirrhosis and keloids, comprising administering to said subject a preparation comprising a protein or biologically active fragment thereof according to any one of claims 22 to 27 or, alternatively, an agent for reducing the expression
10 or activity of native pCL13, optionally in admixture with a suitable pharmaceutically acceptable carrier.

38. A method for diagnosing a disease or condition in a subject, said disease or condition being selected from inflammatory and fibrotic diseases,
15 comprising detecting the presence or activity of the protein designated pCL13 in said subject.

39. A kit for use in a method according to claim 38, said kit comprising a protein or biologically active fragment thereof according to any one of claims
20 22 to 27, or an antibody or fragment thereof according to claim 31.

40. A gene therapy agent comprising a polynucleotide molecule according to any one of claims 1 to 18 or a vector according to any one of claims 19 to 21.
25

41. A receptor molecule specific for a protein designated pCL13, in substantially pure form.



1/34

1 GCGGCCGCTGCACAGCC ATG CCC GGG CAA GAA CTC AGG ACG CTG AAT GGC TCT CAG ATG CTC 62
 1 M P G Q E L R T L N G S Q M L 15
 63 CTG GTG TTG CTG GTG CTC TCG TGG CTG CCG CAT GGG GGC GCC CTG TCT CTG GCC GAG GCG 122
 16 L V L L V L S W L P H G G A L S L A E A 35
 123 AGC CGC GCA AGT TTC CCG GGA CCC TCA GAG TTG CAC ACC GAA GAC TCC AGA TTC CGA GAG 182
 36 S R A S F P G P S E L H T E D S R F R E 55
 183 TTG CGG AAA CGC TAC GAG GAC CTG CTA ACC AGG CTG CGG GCC AAC CAG AGC TGG GAA GAT 242
 56 L R K R Y E D L L T R L R A N Q S W E D 75
 243 TCG AAC ACC GAC CTC GTC CCG GCC CCT GCA GTC CGG ATA CTC ACG CCA GAA GTG CGG CTG 302
 76 S N T D L V P A P A V R I L T P E V R L 95
 303 GGA TCC GGC GGC CAC CTG CAC CTG CGT ATC TCT CGG GCC GCC CTT CCC GAG GGG CTC CCC 362
 96 G S G G H L H L R I S R A A L P E G L P 115
 363 GAG GCC TCC CGC CTT CAC CGG GCT CTG TTC CGG CTG TCC CCG ACG GCG TCA AGG TCG TGG 422
 116 E A S R L H R A L F R L S P T A S R S W 135
 423 GAC GTG ACA CGA CCT CTG CGG CGT CAG CTC AGC CTT GCA AGA CCC CAG GCG CCC GCG CTG 482
 136 D V T R P L R R Q L S L A R P Q A P A L 155
 483 CAC CTG CGA CTG TCG CCG CCG CCG TCG CAG TCG GAC CAA CTG CTG GCA GAA TCT TCG TCC 542
 156 H L R L S P P P S Q S D Q L L A E S S S 175
 543 GCA CGG CCC CAG CTG GAG TTG CAC TTG CGG CCG CAA GCC GCC AGG GGG CGC CGC AGA GCG 602
 176 A R P Q L E L H L R P Q A A R G R R R A 195
 ↓
 603 CGT GCG CGC AAC GGG GAC CAC TGT CCG CTC GGG CCC GGG CGT TGC TGC CGT CTG CAC ACG 662
 196 R A R N G D H C P L G P G R C C R L H T 215
 663 GTC CGC GCG TCG CTG GAA GAC CTG GGC TGG GCC GAT TGG GTG CTG TCG CCA CGG GAG GTG 722
 216 V R A S L E D L G W A D W V L S P R E V 235
 723 CAA GTG ACC ATG TGC ATC GGC GCG TGC CCG AGC CAG TTC CGG GCG GCA AAC ATG CAC GCG 782
 236 Q V T M C I G A C P S Q F R A A N M H A 255
 783 CAG ATC AAG ACG AGC CTG CAC CGC CTG AAG CCC GAC ACG GTG CCA GCG CCC TGC TGC GTG 842
 256 Q I K T S L H R L K P D T V P A P C C V 275
 843 CCC GCC AGC TAC AAT CCC ATG GTG CTC ATT CAA AAG ACC GAC ACC GGG GTG TCG CTC CAG 902
 276 P A S Y N P M V L I Q K T D T G V S L Q 295
 903 ACC TAT GAT GAC TTG TTA GCC AAA GAC TGC CAC TGC ATA TGA GCAGTCCTGGTCTTCCACTGTGC 968
 296 T Y D D L L A K D C H C I • 309
 969 ACCTGCGCGGGGAGGCGACCTCAGTTGCTCTGCCCTGTGGA ATG GGC TCA AGG TTC CTG AGA CAC CCG 1037
 1038 ATT CCT GCC CAA ACA GCT GTA TTT ATA TAA GTCTGTTATTTATTATTAATTTATTGGGGTGACCTTCTTG 1107
 1108 GGGACTCGGGGGCTGGTCTG ATG GAA CTG TGT ATT TAT TTA AAA CTC TGG TGA TAAAAATAAAGCTGT 1175
 1176 CTGAAGTGTAAAAA 1202

↓ Processing site following nucleotide 605
 • Stop codon

FIGURE 1

2/34

FIGURE 2FIGURE 3FIGURE 4

3/34

CEMP2_HUM	CKRHPLYVDFS-DVGANDWTVAPPGYHAFYCHGECFFPLADHLNSTINHAIVQTLVN
CEMP3_HUM	CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFMPKSLKPSNHATTIQSTVR
CEMP4_HUM	CRHSLYVDFS-DVGANDWTVAPPGYQAFYCHGDCFFPLADHLNSTINHAIVQTLVN
CEMP5_HUM	CKKHELYVSFR-DLGWQDWIIAPEGYAIFYCDGECFFPLNAHMAATINHAIVQTLVH
CEMP6_HUM	CKKHELYVSFQ-DLGWQDWIIAPKGYAANYCDGECFFPLNAHMAATINHAIVQTLVH
CEMP7_HUM	CKKHELYVSFR-DLGWQDWIIAPEGYAIFYCEGECAFFPLNSYMAATINHAIVQTLVH
CGDF3_MOUS	CHRHQLFTNFQ-DLGWHKWVIAPKGFMANFYCHGECFFSMITTYLNSSNYAFMQALMH
CGDF9_MOUS	CELHDFSLSFS-QLKWDNWTIVAPHSYNPSYCKGDCPSAVSHRYGSPVHIMVQNMITY
CHSOP1_5	CKKHELYVSFR-DLGWQDWIIAPEGYA-----FPLNSYMAATINHAIVQTLVH
CIHBA_HUM	CCKKQFFVSEFK-DIGANDWIIAPSGYHANYCEGECPSHLAGTSGSSLSFHSSTVINHYRM
CMIS_HUM	CALRELSVDLRAERS-----VLIPTTYQANNQCGVCGWQSDRNPFGNHVLLIKM
CPEP13	CCRLHIVRASLEDLGWADWVLSPREVQVIMCIGACP---SQFRAANMHAQIKTSLH
CTGF1_HUM	CCVRPLYIDFRKDLGWK-WIHEPKGYHANFCLGFCPYTWS---LDTQYSKVLALYN
CTGF2_HUM	CCLRPPLYIDFRKDLGWK-WIHEPKGYANFCAAGACPYLWS---SDTQHSRVLSLYN
CTGF3_HUM	CCVRPLYIDFRQDLGWK-WIHEPKGYANFCSGFCPYLRS---ADTTHSTVLGLYN
CTGF4_CHIC	CCVRPLYIDFRKDLQWK-WIHEPKGYANFCMGFCPYTWS---ADTQYTKVLALYN
CTGF5_X	CCVKPLYINFKDLGWE-----ANYCLGNCPYTWS---MDTQYSKVLALYN
CVG1_X	CKKRHLVVEFK-DVGQNWVIAPQGYMANFYCYGECFPYPLTEILNGSNHAITLQTLVH
	*
CEMP2_HUM	SVNSK--IPKACCVPTLSAISMLYLDENKWLKQNYQDMVEGCGCR
CEMP3_HUM	AVGWVPGIPEPCCVPEKMSLSILFFDENKNWLKVYRMTVESACR
CEMP4_HUM	SVNSS--IPKACCVPTLSAISMLYLDYDKWLKQNYQDMVEGCGCR
CEMP5_HUM	LMFPDH-VPKPCCAPTQLNAISVLYFDDSSNWLKKYRNMVVRACGCH
CEMP6_HUM	LMNPEY-VPKPCCAPTQLNAISVLYFDDSSNWLKKYRNMVVRACGCH
CEMP7_HUM	FINPET-VPKPCCAPTQLNAISVLYFDDSSNWLKKYRNMVVRACGCH
CGDF3_MOUS	MADP-K-VPKAVCVPTKLSPISMLYQDSKQWILRHVEDMVEDECGG
CGDF9_MOUS	E-KLDPSVSPSPSCVPGKYSPLSVLTIEPDGSIAYKGYEDMATSCTCR
CHSOP1_5	FINPET-VPKPCCAPTQLNAISV-----ILKKYRNMVVRACGCH
CIHBA_HUM	RGHSPFANLKSOCVPTKLRLMSMLYDDGQNIKKQIQAMVEECGCS
CMIS_HUM	QARGAALARPPCCVPTAYAG-KLLISLSEERIISAHVRMVADECGCR
CPEP13	RLKPDV-VPAFCCVPASYNEM-VLIQKTDIGVSLQTYEDLLAKCCHCI
CTGF1_HUM	QHNPASAA-PCCVQALEPLPIVYY-VGRTPKVEQLSNMVRACKCS
CTGF2_HUM	TINPEASAS-PCCVQDLEPLTILYY-IGTPKTEQLSNMVRACKCS
CTGF3_HUM	TINPEASAS-PCCVQDLEPLTILYY-VGRTPKVEQLSNMVRACKCS
CTGF4_CHIC	QHNPASAA-PCCVQDLEPLPIIYY-VGRNVRVEQLSNMVRACKCS
CTGF5_X	QNNPGASIS-PCCVP-----YY-VGRTPKVEQLSNMVRACKCS
CVG1_X	SIEPED-IPLPCCVPTKNSPISMLFYDNNENNVLPSTENMAVEDECGCR

FIGURE 5

4/34

```

1 AAGCTT ATG CCC GGG CAA GAA CTC AGG ACG CTG AAT GGC TCT CAG ATG CTC CTG GTG TTG 60
1      M  P  G  Q  E  L  R  T  L  N  G  S  Q  M  L  L  V  L  18

61 CTG GTG CTC TCG TGG CTG CCG CAT GGG GGC GCC CTG TCT CTG GCC GAG GCG AGC CGC GCA 120
19 L  V  L  S  W  L  P  H  G  G  A  L  S  L  A  E  A  S  R  A  38

121 AGT TTC CCG GGA CCC TCA GAG TTG CAC ACC GAA GAC TCC AGA TTC CGA GAG TTG CGG AAA 180
39 S  F  P  G  P  S  E  L  H  T  E  D  S  R  F  R  E  L  R  K  58

181 CGC TAC GAG GAC CTG CTA ACC AGG CTG CGG GCC AAC CAG AGC TGG GAA GAT TCG AAC ACC 240
59 R  Y  E  D  L  L  T  R  L  R  A  N  Q  S  W  E  D  S  N  T  78

241 GAC CTC GTC CCG GCC CCT GCA GTC CGG ATA CTC ACG CCA GAA GTG CGG CTG GGA TCC GGC 300
79 D  L  V  P  A  P  A  V  R  I  L  T  P  E  V  R  L  G  S  G  98

301 GGC CAC CTG CAC CTG CGT ATC TCT CGG GCC GCC CTT CCC GAG GGG CTC CCC GAG GCC TCC 360
99 G  H  L  H  L  R  I  S  R  A  A  L  P  E  G  L  P  E  A  S  118

361 CGC CTT CAC CGG GCT CTG TTC CGG CTG TCC CCG ACG GCG TCA AGG TCG TGG GAC GTG ACA 420
119 R  L  H  R  A  L  F  R  L  S  P  T  A  S  R  S  W  D  V  T  138

421 CGA CCT CTG CGG CGT CAG CTC AGC CTT GCA AGA CCC CAG GCG CCC GCG CTG CAC CTG CGA 480
139 R  P  L  R  R  Q  L  S  L  A  R  P  Q  A  P  A  L  H  L  R  158

481 CTG TCG CCG CCG CCG TCG CAG TCG GAC CAA CTG CTG GCA GAA TCT TCG TCC GCA CGG CCC 540
159 L  S  P  P  P  S  Q  S  D  Q  L  L  A  E  S  S  S  A  R  P  178

541 CAG CTG GAG TTG CAC TTG CGG CCG CAA GCC GCC AGG GGG CGC CGC AGA GCG CGT GAA TTC 600
179 Q  L  E  L  H  L  R  P  Q  A  A  R  G  R  R  R  A  R  E  F  198

601 GAC TAC AAG GAC GAC GAT GAC AAG GCG CGC AAC GGG GAC CAC TGT CCG CTC GGG CCC GGG 660
199 D  Y  K  D  D  D  D  K  A  R  N  G  D  H  C  P  L  G  P  G  218

661 CGT TGC TGC CGT CTG CAC ACG GTC CGC GCG TCG CTG GAA GAC CTG GGC TGG GCC GAT TGG 720
219 R  C  C  R  L  H  T  V  R  A  S  L  E  D  L  G  W  A  D  W  238

721 GTG CTG TCG CCA CGG GAG GTG CAA GTG ACC ATG TGC ATC GGC GCG TGC CCG AGC CAG TTC 780
239 V  L  S  P  R  E  V  Q  V  T  M  C  I  G  A  C  P  S  Q  F  258

781 CGG GCG GCA AAC ATG CAC GCG CAG ATC AAG ACG AGC CTG CAC CGC CTG AAG CCC GAC ACG 840
259 R  A  A  N  M  H  A  Q  I  K  T  S  L  H  R  L  K  P  D  T  278

841 GTG CCA GCG CCC TGC TGC GTG CCC GCC AGC TAC AAT CCC ATG GTG CTC ATT CAA AAG ACC 900
279 V  P  A  P  C  C  V  P  A  S  Y  N  P  M  V  L  I  Q  K  T  298

901 GAC ACC GGG GTG TCG CTC CAG ACC TAT GAT GAC TTG TTA GCC AAA GAC TGC CAC TGC ATA 960
299 D  T  G  V  S  L  Q  T  Y  D  D  L  L  A  K  D  C  H  C  I  318

961 TGA CTCGAG 969
319 • 319

```

↓ = processing site
 underline = FLAG epitope that is fused to amino terminus of bioactive region of clone 13
 • = stop codon

FIGURE 6

5/34

```

1  GCTAGCGCC ATG GAT TAC TAC AGA AAA TAT GCA GCT ATC TTT CTG GTC ACA TTG TCG GTG  60
1      M  D  Y  Y  R  K  Y  A  A  I  F  L  V  T  L  S  V  17
      ↓
61  TTT CTG CAT GTT CTC CAT TCC GCT CCT GAT GAA TTC GAC TAC AAG GAC GAC GAT GAC AAG  120
18  F  L  H  V  L  H  S  A  P  D  E  F  D  Y  K  D  D  D  D  K  37

121 CGT CAG CTC AGC CTT GCA AGA CCC CAG GCG CCC GCG CTG CAC CTG CGA CTG TCG CCG CCG  180
38  R  Q  L  S  L  A  R  P  Q  A  P  A  L  H  L  R  L  S  P  P  57

181 CCG TCG CAG TCG GAC CAA CTG CTG GCA GAA TCT TCG TCC GCA CGG CCC CAG CTG GAG TTG  240
58  P  S  Q  S  D  Q  L  L  A  E  S  S  S  A  R  P  Q  L  E  L  77
      ▼
241 CAC TTG CGG CCG CAA GCC GCC AGG GGG CGC CGC AGA GCG CGT GCG CGC AAC GGG GAC CAC  300
78  H  L  R  P  Q  A  A  R  G  R  R  R  A  R  A  R  N  G  D  H  97

301 TGT CCG CTC GGG CCC GGG CGT TGC TGC CGT CTG CAC ACG GTC CGC GCG TCG CTG GAA GAC  360
98  C  P  L  G  P  G  R  C  C  R  L  H  T  V  R  A  S  L  E  D  117

361 CTG GGC TGG GCC GAT TGG GTG CTG TCG CCA CGG GAG GTG CAA GTG ACC ATG TGC ATC GGC  420
118 L  G  W  A  D  W  V  L  S  P  R  E  V  Q  V  T  M  C  I  G  137

421 GCG TGC CCG AGC CAG TTC CGG GCG GCA AAC ATG CAC GCG CAG ATC AAG ACG AGC CTG CAC  480
138 A  C  P  S  Q  F  R  A  A  N  M  H  A  Q  I  K  T  S  L  H  157

481 CGC CTG AAG CCC GAC ACG GTG CCA GCG CCC TGC TGC GTG CCC GCC AGC TAC AAT CCC ATG  540
158 R  L  K  P  D  T  V  P  A  P  C  C  V  P  A  S  Y  N  P  M  177

541 GTG CTC ATT CAA AAG ACC GAC ACC GGG GTG TCG CTC CAG ACC TAT GAT GAC TTG TTA GCC  600
178 V  L  I  Q  K  T  D  T  G  V  S  L  Q  T  Y  D  D  L  L  A  197

601 AAA GAC TGC CAC TGC ATA TGA CTCGAG  627
198 K  D  C  H  C  I  .  204

```

- underline ▪ FLAG epitope
- ↓ ▪ signal sequence cleavage site following first 24 amino acids representing the FSH leader sequence
- ▪ stop codon
- ▼ ▪ predicted processing site is NOT used and the protein secreted commences after the signal sequence at amino acid 25

FIGURE 7

6/34

```

1 GCTAGCGCC ATG GAT TAC TAC AGA AAA TAT GCA GCT ATC TTT CTG GTC ACA TTG TCG GTG 60
1      M D Y Y R K Y A A I F L V T L S V 17
      ↓
61 TTT CTG CAT GTT CTC CAT TCC GCT CCT GAT GAA TTC GAC TAC AAG GAC GAC GAC GAC AAG 120
18 F L H V L H S A P D E F D Y K D D D D K 37

121 [CTC CGC GCC TCC GTG] GCG CGC AAC GGG GAC CAC TGT CCG CTC GGG CCC GGG CGT TGC TGC 180
38 [L R A S V ] A R N G D H C P L G P G R C C 57

181 CGT CTG CAC ACG GTC CGC GCG TCG CTG GAA GAC CTG GGC TGG GCC GAT TGG GTG CTG TCG 240
58 R L H T V R A S L E D L G W A D W V L S 77

241 CCA CGG GAG GTG CAA GTG ACC ATG TGC ATC GGC GCG TGC CCG AGC CAG TTC CGG GCG GCA 300
78 P R E V Q V T M C I G A C P S Q F R A A 97

301 AAC ATG CAC GCG GAG ATC AAG ACG AGC CTG CAC CGC CTG AAG CCC GAC ACG GTG CCA GCG 360
98 N M H A Q I K T S L H R L K P D T V P A 117

361 CCC TGC TGC GTG CCC GCC AGC TAC AAT CCC ATG GTG CTC ATT CAA AAG ACC GAC ACC GGG 420
118 P C C V P A S Y N P M V L I Q K T D T G 137

421 GTG TCG CTC CAG ACC TAT GAT GAC TTG TTA GCC AAA GAC TGC CAC TGC ATA TGA CTCGAG 480
138 V S L Q T Y D D L L A K D C H C I * 155

```

underline = FLAG epitope
 [] = PKA site
 ↓ = signal sequence cleavage site following first 24 amino acids representing
 the FSH leader sequence
 * = stop codon

FIGURE 8

Figure






FIGURE 9

8/34

FIGURE 10

9/34

FIGURE 11

10/34





FIGURE 12

11/34




FIGURE 13

12/34



thymidine
uptake (dpm)log thymidine
uptake (dpm)

FIGURE 14

13/34



thymidine
uptake (dpm)thymidine
uptake (dpm)

FIGURE 15

14/34



thymidine
uptake (dpm)thymidine
uptake (dpm)

FIGURE 16

15/34




FIGURE 17

16/34





FIGURE 18

17/34




FIGURE 19A

18/34




FIGURE 19B

[illegible]

FIGURE 20A (Cont'd)

SUBSTITUTE SHEET (RULE 26)

		20/34			
		210	220	230	240
201	CATGCCTGGCCCCCAGAAATTATGAATCCTGTGAGGATGGC	b2			
201	CATGCCTGGCCCCCAGAAATTATGAATCCTGTGAGGATGGC	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		250	260	270	280
241	TTCAAGGTGAGCGCTGAGCCAGACAAAAGGATGGGGTTTG	b2			
241	TTCAAGGTGAGCGCTGAGCCAGACAAAAGGATGGGGTTTG	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		290	300	310	320
281	GGAGCACCCCTGCTTAGACTGGAAAGATAATGTTGGAGAAG	b2			
281	GGAGCACCCCTGCTTAGACTGGAAAGATAATGTTGGAGAAG	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		330	340	350	360
321	ACTTCCTGGAAGAGGGGCTTTTTTGCGTAGAGTTTTGAAGA	b2			
321	ACTTCCTGGAAGAGGGGCTTTTTTGCGTAGAGTTTTGAAGA	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		370	380	390	400
361	ATGAGTAGGAGTTCTCCAGAGGAGGATGAGTAACTGCAAT	b2			
361	ATGAGTAGGAGTTCTCCAGAGGAGGATGAGTAACTGCAAT	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			

FIGURE 20A (Cont'd)

21/34

		410	420	430	440	
401	AACACCCAGTTTATCAAGTGCCTCCTATGTGTCTGGCCCT					b2
401	AACACCCAGTTTATCAAGTGCCTCCTATGTGTCTGGCCCT					h1
3	- - - - -					u2
3	- - - - -					f1
3	- - - - -					C13
3	- - - - -					a1
3	- - - - -					b1
3	- - - - -					d2
3	- - - - -					dd2
<hr/>						
		450	460	470	480	
441	GTGCTTTACCCCTCATTTGACCACCTCTCCAGTGAGAGTC					b2
441	GTGCTTTACCCCTCATTTGACCACCTCTCCAGTGAGAGTC					h1
3	- - - - -					u2
3	- - - - -					f1
3	- - - - -					C13
3	- - - - -					a1
3	- - - - -					b1
3	- - - - -					d2
3	- - - - -					dd2
<hr/>						
		490	500	510	520	
481	TCAGTCCTTTTTTTCCTGGTGAGGAAACAGGCATGGCAGA					b2
481	TCAGTCCTTTTTTTCCTGGTGAGGAAACAGGCATGGCAGA					h1
3	- - - - -					u2
3	- - - - -					f1
3	- - - - -					C13
3	- - - - -					a1
3	- - - - -					b1
3	- - - - -					d2
3	- - - - -					dd2
<hr/>						
		530	540	550	560	
521	GAGGCATGACACATCAAGGTTGCCCTTCCTGGCTCCATCT					b2
521	GAGGCATGACACATCAAGGTTGCCCTTCCTGGCTCCATCT					h1
3	- - - - -					u2
3	- - - - -					f1
3	- - - - -					C13
3	- - - - -					a1
3	- - - - -					b1
3	- - - - -					d2
3	- - - - -					dd2
<hr/>						
		570	580	590	600	
561	AGCCCGTTCTCCTCTGCTTCCTTTGTTTTTTCACCATCTTT					b2
561	AGCCCGTTCTCCTCTGCTTCCTTTGTTTTTTCACCATCTTT					h1
3	- - - - -					u2
3	- - - - -					f1
3	- - - - -					C13
3	- - - - -					a1
3	- - - - -					b1
3	- - - - -					d2
3	- - - - -					dd2

FIGURE 20A (Cont'd)

SUBSTITUTE SHEET (Rule 26)

		22/34			
		610	620	630	640
601	AGCCTTTTGACCCCAACCAAAAAGAGAAGAGAGGAAATCCC	b2			
601	AGCCTTTTGACCCCAACCAAAAAGAGAAGAGAGGAAATCCC	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		650	660	670	680
641	ATGGGCATAGACAGCCACCTCTTAAACTCTTGCTCTGGAAAT	b2			
641	ATGGGCATAGACAGCCACCTCTTAAACTCTTGCTCTGGAAAT	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		690	700	710	720
681	TTTTTCACATAGTAACAATGTCTTTTTTTCCTCCAAAAAGAA	b2			
681	TTTTTCACATAGTAACAATGTCTTTTTTTCCTCCAAAAAGAA	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		730	740	750	760
721	CTCCCAGGCTGGAATGGTGCTCCTCATATCGAGGAAGAGGA	b2			
721	CTCCCAGGCTGGAATGGTGCTCCTCATATCGAGGAAGAGGA	h1			
3	- - - - -	u2			
3	- - - - -	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			
		770	780	790	800
761	TACTGAGGCCCAAGAAATGTGCCCCTAGCTTTACTAGGAGCG	b2			
761	TACTGAGGCCCAAGAAATGTGCCCCTAGCTTTACTAGGAGCG	h1			
3	-GCTGAGGCCCAAGAAATGTGCCCCTAGCTTTACTAGGAGCG	u2			
3	-GC-	f1			
3	- - - - -	C13			
3	- - - - -	a1			
3	- - - - -	b1			
3	- - - - -	d2			
3	- - - - -	dd2			

FIGURE 20A (Cont'd)

SUBSTITUTE SHEET (Rule 26)

		23/34			
		810	820	830	840
801	CCCCCACCTAAAGATCCTCCCCCTAAATACACCCCCCAGAC	b2			
801	CCCCCACCTAAAGATCCTCCCCCTAAATACACCCCCCAGAC	h1			
42	CCCCCACCTAAAGATCCTCCCCCTAAATACACCCCCCAGAC	u2			
5	-----	f1			
3	-----	C13			
3	-----	a1			
3	-----	b1			
3	-----	d2			
3	-----	dd2			
		850	860	870	880
841	CCCGCCCAGCTGTGGTTCATTGGAGTGTTTACTCTGTCAGGC	b2			
841	CCCGCCCAGCTGTGGTTCATTGGAGTGTTTACTCTGTCAGAC	h1			
82	CCCGCCCAGCTGTGGTTCATTGGAGTGTTTACTCTGTCAGGC	u2			
5	-----	f1			
3	-----	C13			
3	-----	a1			
3	-----	b1			
3	-----	d2			
3	-----	dd2			
		890	900	910	920
881	AGGGGGAGGAGGGCGGGACTGAGCAGGCGGAGACGGACAA	b2			
881	AGGGGGAGGAGGGCGGGACTGAGCAGGCGGAGACGGACAA	h1			
122	AGGGGGAGGAGGGCGGGACTGAGCAGGCGGAGACGGACAA	u2			
5	-----	f1			
3	-----	C13			
3	-----	a1			
3	-----	b1			
3	-----	d2			
3	-----	dd2			
		930	940	950	960
921	AGTCCGGGGACTATAAAGGCCGGTCCGGCAGCATCTGGTTC	b2			
921	AGTCCGGGGACTATAAAGGCCGGTCCGGCAGCATCTGGTTC	h1			
162	AGTCCGGGGACTATAAAGGCCGGTCCGGCAGCATCTGGTTC	u2			
5	-----CGGGGACTATAAAGGCCGGTCCGGCAGCATCTGGTTC	f1			
3	-----	C13			
3	-----	a1			
3	-----	b1			
3	-----	d2			
3	-----	dd2			
		970	980	990	1000
961	AGTCCCAGCTCAGAGGCCGCAACCTGCACAGCCATGCCCCGG	b2			
961	AGTCCCAGCTCAGAGGCCGCAACCTGCACAGCCATGCCCCGG	h1			
202	AGTCCCAGCTCAGAGGCCGCAACCTGCACAGCCATGCCCCGG	u2			
41	AGTCCCAGCTCAGAGGCCGCAACCTGCACAGCCATGCCCCGG	f1			
3	-----GGC-CG-CTGCACAGCCATGCCCCGG	C13			
3	-----GCG-C-AACCTGCACAGCCATGCCCCGG	a1			
3	-----G--C--C--C--CACAGCCATGCCCCGG	b1			
3	-----GCCGCAACCTGCACAGCCATGCCCCGG	d2			
3	-----GCCGCAACCTGCACAGCCATGCCCCGG	dd2			

FIGURE 20A (Cont'd)

24/34

	1010	1020	1030	1040	
1001	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			b2
1001	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			h1
242	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			u2
81	G C A A G A A C T C A G G A C G C	T G A A T G G C T C T C A G A T G C T C C T G			f1
26	G C A A G A A C T C A G G A C G C	T G A A T G G C T C T C A G A T G C T C C T G			C13
28	G C A A G A A C T C A G G A C G C	T G A A T G G C T C T C A G A T G C T C C T G			a1
19	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			b1
29	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			d2
29	G C A A G A A C T C A G G A C G G	G T G A A T G G C T C T C A G A T G C T C C T G			dd2
	1050	1060	1070	1080	
1041	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				b2
1041	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				h1
282	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				u2
121	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				f1
66	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				C13
68	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				a1
59	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				b1
69	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				d2
69	G T G T T G C T G G T G C T C T C G T G G C T G C C G C A T G G G G G C G C C C				dd2
	1090	1100	1110	1120	
1081	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				b2
1081	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				h1
322	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				u2
161	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				f1
106	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				C13
108	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				a1
99	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				b1
109	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				d2
109	T G T C T C T G G C C G A G G C G A G C C G C G C A A G T T T C C C G G G A C C				dd2
	1130	1140	1150	1160	
1121	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			b2
1121	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			h1
362	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			u2
201	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			f1
146	C T C A G A G T T G C A C A	C C G A A G A C T C C A G A T T C C G A G A G T T G			C13
148	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			a1
139	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			b1
149	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			d2
149	C T C A G A G T T G C A C T	T C C G A A G A C T C C A G A T T C C G A G A G T T G			dd2
	1170	1180	1190	1200	
1161	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				b2
1161	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				h1
402	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				u2
241	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				f1
186	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				C13
188	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				a1
179	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				b1
189	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				d2
189	C G G A A A C G C T A C G A G G A C C T G C T A A C C A G G C T G C G G G C C A				dd2

FIGURE 20A (Cont'd)

SUBSTITUTE SHEET (Rule 26)

25/34

	1210	1220	1230	1240	
1201	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				b2
1201	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				h1
442	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				u2
281	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				f1
226	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				C13
228	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				a1
219	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				b1
229	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				d2
229	A C C A G A G C T G G G A A G A T T C G A A C A C C G A C C T C G T C C C G G C				dd2

	1250	1260	1270	1280	
1241	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				b2
1241	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				h1
482	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				u2
321	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				f1
266	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				C13
268	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				a1
259	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				b1
269	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				d2
269	C C C T G C A G T C C G G A T A C T C A C G C C A G A A G T G C G G C T G G G A				dd2

	1290	1300	1310	1320	
1281	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				b2
1281	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				h1
522	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				u2
361	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				f1
306	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				C13
308	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				a1
299	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				b1
309	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				d2
309	T C C G G C G G C C A C C T G C A C C T G C G T A T C T C T C G G G C C G C C C				dd2

	1330	1340	1350	1360	
1321	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				b2
1321	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				h1
562	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				u2
401	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				f1
346	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				C13
348	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				a1
339	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				b1
349	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				d2
349	T T C C C G A G G G G C T C C C C G A G G C C T C C C G C C T T C A C C G G G C				dd2

	1370	1380	1390	1400	
1361	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				b2
1361	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				h1
602	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				u2
441	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				f1
386	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				C13
388	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				a1
379	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				b1
389	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				d2
389	T C T G T T C C G G C T G T C C C C G A C G G C G T C A A G G T C G T G G G A C				dd2

FIGURE 20A (Cont'd)

26/34

	1410	1420	1430	1440	
1401	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	b2		
1401	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	h1		
642	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	u2		
481	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	f1		
426	G T G A C A C G A C C T	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	C13		
428	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	a1		
419	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	b1		
429	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	d2		
429	G T G A C A C G A C C G	C T G C G G C G T C A G C T C A G C C T T G C A A G A C	dd2		
	1450	1460	1470	1480	
1441	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	b2			
1441	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	h1			
682	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	u2			
521	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	f1			
466	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	C13			
468	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	a1			
459	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	b1			
469	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	d2			
469	C C C A G G C G C C C G C G C T G C A C C T G C G A C T G T C G C C G C C G C C	dd2			
	1490	1500	1510	1520	
1481	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	b2			
1481	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	h1			
722	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	u2			
561	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	f1			
506	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	C13			
508	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	a1			
499	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	b1			
509	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	d2			
509	G T C G C A G T C G G A C C A A C T G C T G G C A G A A T C T T C G T C C G C A	dd2			
	1530	1540	1550	1560	
1521	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	b2			
1521	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	h1			
762	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	u2			
601	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	f1			
546	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	C13			
548	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	a1			
539	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	b1			
549	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	d2			
549	C G G C C C C A G C T G G A G T T G C A C T T G C G G C C G C A A G C C G C C A	dd2			
	1570	1580	1590	1600	
1561	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	b2			
1561	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	h1			
802	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	u2			
641	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	f1			
586	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	C13			
588	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	a1			
579	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	b1			
589	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	d2			
589	G G G G G C G C C G C A G A G C G C G T G C G C G C A A C G G G G A C C A C T G	dd2			

FIGURE 20A (Cont'd)

SUBSTITUTE SHEET (Rule 26)

27/34

	1610	1620	1630	1640	
1601	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				b2
1601	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				h1
842	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				u2
681	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				f1
626	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				C13
628	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				a1
619	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				b1
629	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				d2
629	T C C G C T C G G G C C C G G G C G T T G C T G C C G T C T G C A C A C G G T C				dd2

	1650	1660	1670	1680	
1641	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				b2
1641	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				h1
882	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				u2
721	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				f1
666	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				C13
668	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				a1
659	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				b1
669	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				d2
669	C G C G C G T C G C T G G A A G A C C T G G G C T G G G C C G A T T G G G T G C				dd2

	1690	1700	1710	1720	
1681	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				b2
1681	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				h1
922	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				u2
761	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				f1
706	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				C13
708	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				a1
699	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				b1
709	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				d2
709	T G T C G C C A C G G G A G G T G C A A G T G A C C A T G T G C A T C G G C G C				dd2

	1730	1740	1750	1760	
1721	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				b2
1721	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				h1
962	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				u2
801	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				f1
746	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				C13
748	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				a1
739	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				b1
749	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				d2
749	G T G C C C G A G C C A G T T C C G G G C G G C A A A C A T G C A C G C G C A G				dd2

	1770	1780	1790	1800	
1761	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				b2
1761	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				h1
1002	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				u2
841	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				f1
786	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				C13
788	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				a1
779	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				b1
789	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				d2
789	A T C A A G A C G A G C C T G C A C C G C C T G A A G C C C G A C A C G G T G C				dd2

FIGURE 20A (Cont'd)

28/34

	1810	1820	1830	1840	
1801	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				b2
1801	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				h1
1042	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				u2
881	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				f1
826	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				C13
828	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				a1
819	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				b1
829	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				d2
829	C A G C G C C C T G C T G C G T G C C C G C C A G C T A C A A T C C C A T G G T				dd2
	1850	1860	1870	1880	
1841	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				b2
1841	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				h1
1082	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				u2
921	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				f1
866	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				C13
868	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				a1
859	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				b1
869	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				d2
869	G C T C A T T C A A A A G A C C G A C A C C G G G G T G T C G C T C C A G A C C				dd2
	1890	1900	1910	1920	
1881	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				b2
1881	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				h1
1122	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				u2
961	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				f1
906	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				C13
908	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				a1
899	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				b1
909	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				d2
909	T A T G A T G A C T T G T T A G C C A A A G A C T G C C A C T G C A T A T G A G				dd2
	1930	1940	1950	1960	
1921	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				b2
1921	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				h1
1162	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				u2
1001	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G G G A G G C				f1
946	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G G G A G G C				C13
948	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G G G A G G C				a1
939	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				b1
949	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				d2
949	C A G T C C T G G T C C T T C C A C T G T G C A C C T G C G C G G A G G A C G C				dd2
	1970	1980	1990	2000	
1961	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				b2
1961	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				h1
1202	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				u2
1041	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				f1
986	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				C13
988	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				a1
979	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				b1
989	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				d2
989	G A C C T C A G T T G T C C T G C C C T G T G G A A T G G G C T C A A G G T T C				dd2

FIGURE 20A (Cont'd)

29/34

	2010	2020	2030	2040
2001	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			b2
2001	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			h1
1242	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			u2
1081	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			f1
1026	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			C13
1028	CTGA[A]ACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			a1
1019	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			b1
1029	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			d2
1029	CTGAGACACCCGATTTCCTGCCCCAAACAGCTGTATTTATAT			dd2

	2050	2060	2070	2080
2041	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			b2
2041	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			h1
1282	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			u2
1121	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			f1
1066	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			C13
1068	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			a1
1059	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			b1
1069	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			d2
1069	AAGTCTGTATTATTTATTTAATTATTTGTTGACCTTCT			dd2

	2090	2100	2110	2120
2081	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			b2
2081	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			h1
1322	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			u2
1161	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			f1
1106	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			C13
1108	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			a1
1099	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			b1
1109	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			d2
1109	TGGGGACTCGGGGGGCTGGTCTGATGGAACCTGTGTATTTAT			dd2

	2130	2140	2150	2160
2121	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			b2
2121	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			h1
1362	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			u2
1201	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			f1
1146	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			C13
1148	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			a1
1139	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			b1
1149	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			d2
1149	TTAAAACTCTGGTGATAAAAAATAAAGCTGTCTGAACCTGTT			dd2

	2170	2180	2190	2200
2161	AAAAAAAAAAAAAAAAAAAA			b2
2161	AAAAAAAAAAAAAAAAAAAA			h1
1402	AAAAAAAAAAAAAAAAAAAA			u2
1241	AAAAAAAAAAAAAAAAAAAA			f1
1186	AAAAAAAAAAAAAAAAAAAA			C13
1188	AAAAAAAAAAAAAAAAAAAA			a1
1179	AAAAAAAAAAAAAAAAAAAA			b1
1189	AAAAAAAAAAAAAAAAAAAA			d2
1189	AAAAAAAAAAAAAAAAAAAA			dd2

FIGURE 20A (Cont'd)

2210

2220

2230

2177

2178

1442 A A A A A A A A A A A A A A A

1256

1202

1228 A A A A A A A A A A

1219 A A A A A A A A A A A A A A A A A A A N A A A A N A A A A A A A

1205

1229 A

b2

h1

 u_2

f1

C13

a1

b1

42

dd2

Decoration 'Decoration #1': Box residues that differ from C13dnaseq.def.

FIGURE 20A (Cont'd)

31/34

	10	20	30	40	
1	M P G Q E L R T L N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				C13
1	M P G Q E L R T L N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				a1
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				b1
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				b2
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				d2
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				dd2
1	M P G Q E L R T L N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				f1
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				h1
1	M P G Q E L R T V N G S Q M L L V L L V L S W L P H G G A L S L A E A S R A S F				u2

	50	60	70	80	
41	P G P S E L H T E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				C13
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				a1
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				b1
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				b2
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				d2
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				dd2
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				f1
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				h1
41	P G P S E L H S E D S R F R E L R K R Y E D L L T R L R A N Q S W E D S N T D L				u2

	90	100	110	120	
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				C13
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				a1
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				b1
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				b2
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				d2
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				dd2
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				f1
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				h1
81	V P A P A V R I L T P E V R L G S G G H L H L R I S R A A L P E G L P E A S R L				u2

	130	140	150	160	
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				C13
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				a1
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				b1
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				b2
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				d2
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				dd2
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				f1
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				h1
121	H R A L F R L S P T A S R S W D V T R P L R R Q L S L A R P Q A P A L H L R L S				u2

	170	180	190	200	
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				C13
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				a1
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				b1
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				b2
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				d2
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				dd2
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				f1
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				h1
161	P P P S Q S D Q L L A E S S S A R P Q L E L H L R P Q A A R G R R R A R A R N G				u2

FIGURE 20B

		32/34		
	210	220	230	240
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	C13
201	D ¹ HCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	a1
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	b1
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	b2
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	d2
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	dd2
201	D ¹ HCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	f1
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	h1
201	DHCPLGPGRCCRLHTV	SLLEDLGWADWVLS	PREVQVTMC	u2
<hr/>				
	250	260	270	280
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN C13
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN a1
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN b1
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN b2
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN d2
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN dd2
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN f1
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN h1
241	IGACPSQFRAANMHAQ	IKTSLHRLKPD	TVPA	PCCVPASYN u2
<hr/>				
	290	300		
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	C13
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	a1
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	b1
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	b2
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	d2
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	dd2
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	f1
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	h1
281	PMVLIQKTD	TGVSLQTYDDL	LAKDCHCI	u2

Decoration 'Decoration #1': Box residues that differ from C13protseq.def.

FIGURE 20B (Cont'd)

33/34

C13SA/5HNUCLEOTIDE SEQUENCE

		10		20		30		40			50		60		70		80															
1	G	C	T	A	G	C	G	C	C	A	T	G	G	T	C	A	T	T	C	T	G	C	A	T	T	C	C	A	T	T	C	80
81	C	G	T	C	C	T	G	A	T	T	C	C	A	C	C	A	C	C	A	C	C	T	G	T	G	C	C	C	C	G	C	160
161	C	C	T	C	C	G	T	G	G	C	G	C	A	C	G	G	G	G	A	C	C	T	G	T	C	G	C	C	G	C	G	240
241	G	A	A	G	A	C	C	T	G	G	C	C	G	A	T	T	G	G	G	T	G	C	T	G	T	C	G	C	C	G	C	320
321	G	T	T	C	C	G	G	G	C	G	A	A	C	A	T	G	C	A	C	G	C	A	G	A	T	C	G	G	C	G	C	400
401	G	C	G	T	G	C	C	C	G	C	A	G	T	A	C	A	A	T	C	C	A	T	G	T	G	C	T	C	A	T	T	480
481	T	T	A	G	C	C	A	A	G	A	C	T	G	C	C	A	C	T	G	A	G	C	C	C	G	A	T	G	A	C	T	513
		10		20		30		40			50		60		70		80															

TRANSLATED PROTEIN SEQUENCE

		10		20		30		40			50		60		70		80																																																												
1	L	E	K	R	E	H	H	H	H	L	V	P	R	G	S	D	Y	K	D	<u>DDDK</u>	L	R	A	S	V	A	R	N	G	D	H	C	P	L	G	P	G	R	C	C	R	L	H	T	V	R	A	S	L	E	D	L	G	W	A	D	W	V	L	S	P	R	E	V	Q	V	T	M	C	I	G	A	C	P	S	Q	80
81	F	R	A	A	N	M	H	A	Q	I	K	T	S	L	H	R	L	K	P	D	T	V	P	A	P	C	C	V	P	A	S	Y	N	P	M	V	L	I	Q	K	T	D	G	V	S	L	Q	T	Y	D	D	L	L	A	K	D	C	H	C	I	•	142															
		10		20		30		40			50		60		70		80																																																												

underline = FLAG epitope

 = PKA site

↓ = yeast signal sequence cleavage site amino acid 5

• = stop codon


┌───┐ = motif of 5 HIS residues for binding to metal chelate column

coding region for bioactive part of clone 13 commences with amino acid 30

LVPRGS = this sequence from amino acids 11-16 represents thrombin cleavage site

FIGURE 21

Unreduced



Reduced




FIGURE 22

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 96/00386

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁹: C12N 15/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

INT CL⁹ C12N 15/19; WPAT, CHEM ABS, JAPIO

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA SEQUENCE SEARCH - FIGURES 1, 7 & 8

WPAT: JAPIO: KEYWORDS:- (TUMOR or TUMOUR)(W) GROWTH (W) FACTOR#(W)(B## or BETA:) or TGF(W)(B## or BETA)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Guidebook to Cytokines and their Receptors; Transforming Growth Factor- β (TGF β) pp223-226	
P,X	AU,A1,18301/95 (HUMAN GENOME SCIENCES INC) 20 June 1996 See complete document and page 39 in particular	1-18, 31-34, 36, 37
P,X	JP,A,7-258293 (ASAHI CHEMICAL IND.) 9 October 1995, discloses A.A. sequence 197-308, see pages 2 and 20; English Abstract CA A.N. 124:80724	1-41



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 September 1996

Date of mailing of the international search report

30 SEPT 1996

Name and mailing address of the ISA/AU
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

JOHN ASHMAN

Telephone No.: (06) 285 2364

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 96/00386

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	JP,A,7-250688 (SAGAMI CHEMICAL RESEARCH) 3 October 1995, discloses A.A. sequence 211-308, see page 7; English Abstract CA, AN 124:22549	1-41
X	WO 94 03599, A1, (SAGAMI CHEMICAL RESEARCH) 17 February 1994, discloses A.A. sequence 210-308, see seq I.D. 67; English Abstract: CA, AN 120:317349	1-41

INTERNATIONAL SEARCH REPORT

PCT/AU 96/00386

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
WO	9403599	US	5450780
AU	18301/95	WO	9618730